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ABSTRACT
CD28 co-stimulation is required for the generation of naturally occurring
regulatory T cells (nTregs) in the thymus through Lck-signaling. However, high level of
CD28 suppresses the generation of induced Tregs (iTregs) from naïve CD4 T cells,
although underlying mechanism(s) has not been defined. Here we investigated the role of
CD28-mediated signaling pathways in the suppression of Treg generation. We used a
series of transgenic (Tg) mice on CD28-deficient background that bears WT CD28 or
mutated CD28 in its cytosolic tail incapable of binding to Lck, PI3K or Itk. Regardless of
exogenous IL-2, strong CD28 costimulation suppressed iTreg generation through Lck
signaling. Using a GVHD model to test the role of CD28-mediated iTreg suppression in
T cell pathogenicity in vivo, we found that CD28-Lck T cells induced significantly less
GVHD than T cells from CD28-WT mice. Furthermore, we found that the recipients of T
cells from CD28-Lck mice generated significantly more iTregs than those with T cells
from CD28-WT, which contribute to reduced graft-versus-host disease (GVHD)
development in recipients of CD28-Lck T cells. These results indicate that CD28
costimulation can negatively regulate Treg generation and may provide an avenue for
control of T-cell immunity or tolerance by regulating Tregs using the CD28 signal as a
target. We went a step forward and investigated the therapeutic potential of antigenspecific iTregs in the prevention of GVHD. Donor hematopoietic stem cells and mature T
cells are transplanted into a lymphopenic host to potentially cure many cancers and
hematopoietic diseases like leukemia in bone marrow transplantation (BMT) or
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hematopoietic stem cell transplantation (HCT), but the frequent development of GVHD is
the main drawback of this treatment. nTregs suppress the development of GVHD and
may spare the graft-versus-tumor activity. However, nTregs are a minor (~5%)
subpopulation of CD4 helper T cells in healthy individuals, and using in vitro expanded
nTregs is a common strategy to test their therapeutic potential in BMT. The concern of in
vitro expanded nTregs may include their stability of Foxp3 (master regulatory gene for
the development and function of regulatory T cell) expression and suppressive function,
survival in vivo, and the non-selective suppression of the pre-activated nTregs. Antigenspecific activation of the regulatory T cells is important for optimal function. In this
study, we used an alternative strategy to generate antigen-specific, iTregs and assessed
their suppressive potential by comparing their effectiveness in preventing GVHD with
polyclonal iTregs. We found that antigen-specific iTregs prevented GVHD lethality in
recipients that expressed the target antigen, but were not protective of recipients who did
not express the target antigen. Furthermore, antigen-specific iTregs were significantly
more efficient than those polyclonal Tregs in the prevention of GVHD. These results
reveal the therapeutic potential of antigen-specific iTregs to prevent GVHD efficiently
and selectively, and provide the rationale to use antigen-specific iTregs in clinical HCT.
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CHAPTER 1.
INTRODUCTION
Regulatory T cells.
Manipulating the suppressive population of T cells is an exciting possibility in the
field of immunology, especially in autoimmunity and graft rejection. Lymphocytes with
the ability to induce tolerance were first described in the early 1970s [1, 2]. During the
1980’s, appearance of naturally occurring suppressor T cells in spleens of neonatal or
irradiated mice were temporarily related to the ease of induction of tolerance [3]. These
naturally occurring suppressor cells inhibited the antigen-specific cytolytic arm of
alloreactive immune responses, but left intact the antigen-specific suppressive arm of the
immune response [3]. However, the concept of a specialized population of suppressor
cells was not well understood and it was not until the 1990’s that research on suppressor
T cells was revisited. Subsets of syngeneic CD4+ T cells were depleted and the remaining
CD4+ T cells were transferred into lymphopenic hosts and evaluated for the development
of autoimmunity [4-6]. The transfer of CD25+-depleted CD4+ T cells into athymic nude
mice resulted in systemic multiorgan autoimmune syndromes. Sakaguchi et al also
reported that CD25, the interleukin-2 (IL-2) receptor α-chain found on CD5hi and
CD45RBlo subsets of CD4 T cells is an important surface marker for suppressor cells [5].
However, on a per-cell basis, CD4+CD25+ T cells were more potent than CD5hi or
CD45RBlo T cells in preventing the incidence and severity of autoimmunity [5].

The suppressor T cells were renamed regulatory T cells (Tregs), even though
regulatory T cells might both enhance or suppress immune responses [7]. The neonatal
thymectomy experiments that were conducted with the discovery of Tregs revealed that
Tregs are developed in the thymus. Almost undetectable levels of peripheral CD4+CD25+
T cells were present one week after thymectomy done on day 3, and much less splenic
CD4+CD25+ T cells were detected in the thymectomized adult mice when compared with
unmanipulated controls [8]. It should be noted that these results determined that the
CD4+CD25+ regulatory T cells prevented autoimmunity not only in the neonatally
thymectomized mice, but also in the lymphopenic animals [5, 9]. After the identification
of Tregs, characterizing the phenotype of these regulatory cells was the focus of many
researchers. CD4+CD25+ T cells were still the accepted phenotype of Tregs. However,
this phenotype was not reliable since CD25; the high-affinity subunit of the IL-2 receptor
was a T cell activation marker. Rudensky’s group and others reported that Foxp3, a
member of the forkhead winged-helix family of transcription factor was required for the
control of regulatory T cell development and also for its function [10, 11]. The role of
Foxp3 in humans is not as clear-cut as in mice. Foxp3 is the most specific marker for
Tregs and when overexpressed in conventional effector T cells (Teffs), these Teffs can be
converted into suppressive T cells which function like Treg cells [12]. Mutation in the
Foxp3 transcription factor results in scurfy mouse and an autoimmune syndrome in
humans known as immunedysregulation, polyendocrinopathy, and enteropathy, x-linked
(IPEX) [13].
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Naturally-derived regulatory T cells.
Two types of CD4 T regulatory cells are described based on their origin; naturally
derived regulatory T cells and regulatory cells induced in response to antigenic challenge
[14]. Natural T regulatory cells are generated in the thymus and migrate to the periphery
as regulatory cells [15]. Tregs account for approximately 5-10% of peripheral CD4+ in
mice and a slightly smaller fraction in humans [16]. It is believed that thymic stromal
cells, including cortical and medullary thymic epithelial cells and dendritic cells (DCs)
contribute to the differentiation of nTregs, but there is controversy regarding to what
extent the stromal cell components are required for this process [17, 18]. Relatively little
is known about the developmental requirements of regulatory T cells [7]. However,
thymic development of nTreg cells requires high-affinity interactions between their T cell
receptor (TCR) and self-peptide-major histocompatibility complex (MHC) presented by
thymic stromal cells [19]. Conventional CD4+ T cells (Tconv) also require MHC class II
expression and interaction with TCR for their development, but they are low-affinity
peptide-MHC class II interactions that result in positive selection [20-22]. There is also a
requirement of Foxp3 for nTreg development in the thymus [10, 11], but the need for
costimulation in the thymus of Treg development is not well understood [23] because
costimulation in the thymus pushes conventional CD4+ cells to undergo negative
selection [24-26]. Sakaguchi et al found that costimulatory signals are necessary for
nTreg development because the number of nTregs in the thymus decrease after the loss of
CD40 or CD28 expression [27]. However, how CD28 costimulation promote generation
and maintenance of Tregs is not fully understood, but it is possible that CD28
costimulation increases the avidity of intrathymic TCR engagement for stimulating Treg
3

generation or that Tregs require CD28 costimulation for survival and expansion since
CD28 costimulation promotes IL-2 secretion [23]. One study reported that both IL-2 and
IL-7 in the thymic microenvironment are required for the development of nTregs in mice
[28]. However, in a definitive study, Tai et al reported that costimulatory signals through
the Lck-binding motif in the CD28 cytosolic tail initiate Treg differentiation in
thymocytes [23].

Functions of regulatory T cells.
Tregs are indispensable for maintaining immunological self-tolerance and
immune homeostasis and are critical for preventing activation of auto reactive T cells [29,
30]. These cells suppress the activation, proliferation and effector functions which
includes cytokine production of immune cells like CD4+ and CD8+ T cells, natural killer
(NK) and NKT cells, B cells and other antigen presenting cells (APCs) in vitro and in
vivo [27]. Tregs inhibit the differentiation of naive T cells into Th1 and Th2 [31] and
suppress their immune responses in the prevention of autoimmunity [32]. The ability to
suppress immune responses allows Tregs to prevent the development of autoimmune
disease, immunopathology and allergy, and also function in the maintenance of allograft
tolerance and fetal-maternal tolerance during pregnancy [33]. Recent evidence indicates
that the use of Tregs (CD4+Foxp3+) is one of the promising approaches to control Graftversus-Host-Disease (GVHD) in numerous mouse models [34-39] in addition to early
clinical trials [40, 41]. Tregs have a promising potential as immunotherapy for the
induction of tolerance in autoimmunity and organ and bone marrow transplantation [42].
4

With the recent identification of a new lineage of differentiated naïve T cells,
Th17, studies have focused on the role of Tregs in controlling the Th17 cells. A recent
study found that Tregs have an inhibitory role on Th17 differentiation and the IL-17
production, much like the effect on Th1 and Th2 differentiation [43]. However, some
reports indicate that Th17 cells are not inhibited but rather enhanced by Tregs [44, 45]. Li
et al investigated the role of Tregs on IL-17 production in the absence of exogenous
polarizing cytokines and found that simultaneous activation of naive Tconv and Tregs in
the presence of APC induced differentiation of Tregs but not Tconv into IL-17 producers,
and IL-1β was mandatory for this function [46].

Mechanisms of suppression.
There are many unresolved issues pertaining to the suppressive functions of
Tregs, but several fundamental conclusions are widely accepted. It is generally accepted
that Tregs are activated by either antigen-specific TCR ligation or the presence of
polyclonal stimuli [47, 48]. However, after the Tregs are activated, they can suppress in a
non-antigen specific manner [47, 49]. Even though cell contact between the suppressor
and responder cells is required for nTreg suppression [50, 51], the type of cells that the
Tregs target whether the CD25- or the APCs is still controversial [7]. However, Tregs
have been shown to inhibit the expansion of Teffs in vivo [35]. A recent study by Tawara
et al found that alloantigen expression by the host APCs is necessary and sufficient for
induction of GVHD protection by donor Tregs. [52]. The main mechanism of suppression
seemed to be inhibition of IL-2 transcription in the responder population [7]. Because of
5

the indiscriminate nature of Treg suppression, the important antitumor immune responses
may also be suppressed, which may allow the progression of tumor in the body.
Therefore, even though immunologists have been continually working to define Treg
cells at the molecular level [53, 54]; more studies are still needed to understand the
immunobiology of Tregs.

Induced regulatory T cells.
Induced regulatory T cells (iTregs) have identical phenotype as nTregs, but are
differentiated from conventional CD4+ T cells when exposed to specific stimuli in the
periphery which includes altered activation signals or modulating cytokines [15]. In vitro,
iTregs can be generated from naïve CD4+CD25-Foxp- T cells after TCR-stimulation with
additional TGFβ [55]. TGFβ also inhibits T-cell proliferation, the production of proinflammatory cytokines, and is involved in cell cytolysis [56]. It was reported that
immune regulation of iTregs occurs preferentially through the release of soluble factors
such as the suppressive cytokines IL-10 and TGFβ [48, 57, 58]. TGFβ and IL-2 induce
naïve CD4+ T cells to become Foxp3+ iTregs [59, 60], while the combination of TGFβ
and IL-6 induces the production of IL-17-producing cells (Th17) [44, 61-63]. It is
believed that there is plasticity between the Treg and Th17 lineages because of the role of
the common suppressive cytokine TGFβ [64]. Xu et al reported that nTregs can be
induced by IL-6 to become Th17 cells in the absence of TGFβ [65]. In contrast, Zheng et
al found that iTregs failed to become Th17 when stimulated with IL-6 [66]. The apparent
resistance of iTregs to Th17 conversion suggests a more effective role than nTregs in an
6

inflammatory milieu and may suggest a role for IL-2 and TGFβ in maintaining
immunological homeostasis [66].
Because of the infrequency of the nTreg population in peripheral blood, they will
have to be expanded with anti-CD3/anti-CD28 coated microbeads or allogeneic APCs to
attain adequate numbers for therapeutic use. Even though the expansion of nTregs is
feasible, there are a number of issues that prevent the application of expanded nTregs in
the clinic. These include the stability of their Foxp3 expression, their suppressive
function and survival in vivo and the non-selective suppression of pre-activated
polyclonally-expanded nTreg. Because of these issues, there has been effort towards the
use of iTregs instead of expanded nTregs, which is a major portion of research in this
dissertation. iTregs were previously used in the treatment of autoimmune diseases [67].
Also, it was recently reported that iTregs are significantly more potent at suppressing Tcell activation in vitro and are equally effective as freshly isolated nTregs at attenuating
chronic colitis in vivo [68].

Other T cells with regulatory functions.
In addition to CD4+CD25+FOXP3+ Treg cells, other T cells also possess
regulatory activity in mice. The CD4+ T cell subsets are induced in the periphery and
include the CD4+IL-10+Foxp3- (TR1) cells, which secrete IL-10 and the CD4+TGFβ+
(TH3) cells which secrete TGFβ and have been reported in in vivo-induced oral tolerance
in mice [69]. Other subsets of regulatory cells include CD8+ T cells which have
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phenotypic and functional features similar to CD4+ Tregs [70-72]. However, most of
these subsets of cells like the IL-10-secreting TR1 cells, the TGFβ-secreting T helper 3
(TH3) cells, the CD4-CD8- T cells and the CD8+CD28- T cells can acquire their regulatory
functions after antigenic stimulation in the periphery, which is in contrast to nTregs,
which are developed in the thymus with specialized suppressive function [70-72]. Our
study focuses on Foxp3+ nTregs and iTregs.

CD28 Costimulation
T cell activation.
T cell activation requires the recognition of specific peptide-MHC on the surface
of APCs. Foreign protein antigens compete with self-antigens for binding to MHC and
thus T cells have evolved to recognize low numbers of specific peptide-MHC complexes.
The low numbers of peptide-MHC interactions and the low affinity of TCR for peptideMHC complexes are not sufficient for effective T cell activation. Thus, interactions
between costimulatory molecules present on the T cells and APCs provide the second
signal that is required for effective T cell activation. The costimulatory molecules are
important to the immune system and manipulating these molecules may provide pertinent
information for control of the immune response. CD28 is the major costimulatory
molecule present on T cells and provides the second signal for effective T cell activation.
There is therapeutic interest in CD28 costimulation because manipulating these
costimulatory signals might provide a means either to enhance or to terminate the
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immune response [73]. CD28 is a useful target for immune-regulation because of its
costimulatory function. The ligands of the CD28 receptor, B7-1 (CD80) and B7-2
(CD86) are expressed mainly on B cells, DCs, and thymic medullary epithelial cells,
although other cells may have a low expression [73]. CD28 amplifies TCR signals and
positively regulates T cell activation [73]. CD28 costimulation reduces the number of
TCRs that must be triggered to achieve T-cell activation, and enhance T cell survival and
proliferation, as well as the production of cytokines and cytokine receptors.

Treg generation.
Another important function of CD28 costimulation apart from T cell activation
involves the generation of nTregs in the thymus and their survival and homeostasis in the
periphery. It was noted previously that prevention of CD28 ligation with CTLA4-Ig
exacerbated autoimmune disease in non-obese diabetic (NOD) mice [74]. Likewise, NOD
mice develop more rapid and severe autoimmune diabetes in CD28 KO background as
compared with WT mice, which suggest a role for CD28 in autoimmunity. Furthermore,
mice deficient in CD28 or its ligands have reduced numbers of nTregs [74], which further
linked CD28 with a role in nTreg generation. CD28 KO mice lack potent costimulation
for T effector cells and also for nTregs, the most effective mediators of self-tolerance and
result in a balanced deficit that results in the preservation of Ag-mediated activation [75].
However, IL-2 is dispensable for the induction of Foxp3 expression and nTreg
development in the thymus, but it is essential for the survival and homeostasis of nTregs
in the periphery [76]. CD28 costimulation was shown to be important for nTreg survival
9

and homeostasis in the periphery [76]. In a recent study it was demonstrated conclusively
that CD28 costimulation is essential for nTreg development in the thymus independently
of IL-2, even when TCRs are engaged in high-affinity interactions with their agonist
antigen [23]. Our group subsequently reported that CD28 costimulation is critical for
iTreg generation in the periphery and the requirement of CD28 in iTreg generation is also
dependent on IL-2 production [77]. Efficient development of nTregs in the thymus relies
on CD28 costimulation through its cytosolic Lck-binding motif and c-Rel leading to
activation of NF-κB [78-80]. Recently, Vang et al reported that Cd28(-/-) mice lack Treg
progenitors [81]. It is necessary to understand the developmental requirements of Tregs
in order to effectively utilize these cells in immune therapy.

CD28-mediated signaling in Treg generation
The CD28 receptor lacks catalytic activity and therefore relies on associated
kinases to execute its functions [82]. CD28 cytoplasmic domain has multiple motifs that
recruit and activate Lck, PI3K and Itk kinases, which in turn mediate distinct CD28
functions. Upon T cell stimulation, the cytoplasmic tail of CD28 is phosphorylated at
Tyr170 (in the context of YMNM) and creates a docking site for Src homology (SH)2
domain-containing proteins. A point mutation of this motif (F170MNM) compromises T
cell survival due to failure of Bcl-XL up-regulation, but does not affect Treg generation in
the thymus [23]. The PI3K-regulated pathway is one of the major signaling pathways and
is activated by TCR, IL-2R, and CD28 stimulation, leading to T-cell activation,
proliferation, and cell survival [83]. Akt, a serine-threonine kinase, is a key downstream
10

effector of the PI3K signaling pathway, which in response to PI3K activation,
phosphorylates and regulates the activity of various targets including kinases,
transcription factors and other regulatory molecules. Akt functions as a key regulator of
various critical cell functions including glucose metabolism, cell proliferation and
survival.

Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HCT) is a curative therapy for
many hematologic, some epithelial malignancies, and a variety of non-malignant diseases
[84]. HCT represents the most effective treatment for patients with high risk and relapsed
hematologic malignancies [12]. However, donor T cells included in the graft react with
recipient alloantigens present on APCs and produce a syndrome consisting of diarrhea,
weight loss, skin changes, and liver abnormalities called GVHD. Despite the enormous
potential of HCT, the risks associated with GVHD limit its extensive application [85].
Billingham, an early pioneer in the field of BMT, described three requirements for the
development of GVHD [86]. First, the donor graft must contain immunologically
competent cells (mature T cells). It was seen in both experimental and clinical allogeneic
BMT that the severity of GVHD correlates with the number of donor T cells transfused
[87]. Second, the recipient must be immune-compromised and incapable of rejecting the
transplanted cells. And, finally the recipient must express tissue antigens that are not
present in the transplant donor [87].
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Direct and indirect presentation.
After allogeneic HCT transplants, both host- and donor-derived APCs are present
in secondary lymphoid organs [88-90]. The donor T cells that are included in the graft
recognize host alloantigens that are presented by either host APCs (direct presentation) or
donor APCs (indirect presentation) [91, 92]. In the case of direct presentation, the donor
T cells recognize either peptide bound to allogeneic MHC molecules or allogeneic MHC
molecules without peptide [91, 93], whereas in indirect presentation, T cells respond to
the peptide generated by degradation of the allogeneic MHC molecules which are
presented on self-MHC [93]. It was previously reported that host APCs, rather than donor
APCs, are important for GVHD induction in MiHA mismatch [92]. Studies indicate that
presentation of distinct target antigens by the host and donor type APCs might play a
differential role in mediating damage to target organs [92, 94, 95]. Additionally, recent
findings indicate that alloreactive Tregs specific for both directly and indirectly presented
alloantigens are required for the induction of tolerance in organ transplantation [96, 97].

Effect of immunosuppressive agents.
Immunosuppressive agents are included as an essential component of the
allogeneic HCT regimen to reduce the risks of developing GVHD [16]. These
immunosuppressive drugs impair T cell function and may protect from GVHD.
Tacrolimus (TAC) and methotrexate (MTX) used in combination constitute the current
standard of care for GVHD prevention after allogeneic HCT [98]. Randomized clinical
trials have shown that TAC/MTX is superior to Cyclosporin (CSA)/MTX in the
prevention of acute GVHD. It was reported that Grade II-IV acute GVHD was
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significantly lower with TAC/MTX compared to CSA/MTX in both sibling donor (32%
vs. 44%; p=0.01), and unrelated donor (56% vs. 74%; p= 0.0002) transplant trials [99,
100]. TAC and CSA are calcineurin inhibitors, while rapamycin (RAPA) or serolimus
and mycophenolate mofetil acid (MMF) are immunosuppressants which affect the
activation and function of T cells [101]. RAPA inhibits the mTOR pathway activity
which is located downstream of IL-2/PI3K signaling. The mTOR pathway is a
downstream target of Akt phosphorylation and has been linked to the PI3K signaling
pathway, but the exact mechanism for connection is unknown. The mTOR signaling
pathway is one of the targets of B7:CD28 co-stimulation and plays a critical role in the
control of cap-dependent mRNA translation, cell growth, and proliferation [102]. RAPA
inhibits protein kinase activity of the mTOR/raptor complex 1 and is currently used to
prevent allograft rejection as well as an antineoplastic agent, because of its antiproliferative property [103].
Tregs appear to be relatively resistant to effects of RAPA, and the drug may even
promote generation of Tregs in vitro or allow their selective outgrowth in culture [104106]. It was recently reported that RAPA has potent antiproliferative effects on antigenstimulated CD4+ T cells and can promote the conversion of the naïve CD4+ T cells into
Tregs in vivo and even promote their persistence in vivo [103]. RAPA reduces the
expansion of Tconv in vivo, but does not affect the phenotype of Tregs or the expression
of homing molecules, which suggests that RAPA uses different means to inhibit mTOR.
However, it was also shown that RAPA did not affect the polyclonal expansion of donortype Tregs after transplantation [107]. Additionally, there is a synergistic protective effect
of Treg and RAPA against acute GVHD-related morbidity and mortality based on
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reduced expansion of conventional T cells after BMT [107]. Immunosuppression greatly
impairs immune reconstitution and increases the risk of infection while at the same time
it diminishes and can even completely abrogate the important T cell-mediated graftversus-leukemia (GVL) effect [108]. For these reasons, it is absolutely necessary to
provide an alternative treatment option to immunosuppressive agents following HCT.

Graft-versus-Host Disease
GVHD, one of the major complications of allogeneic HCT is caused by donor T
cells reacting against host alloantigens. These same alloreactive donor T cells can provide
the beneficial GVL effect as well resulting in reduction in leukemia relapse [12]. These T
cells also promote hematopoietic engraftment and reconstitute T cell immunity especially
in adults with reduced thymic function [108]. The first step in the development of GVHD
results in activation of the APCs [85]. BMT conditioning regimens administered before
the infusion of donor cells along with the underlying disease and infections result in
tissue damage and secretion of pro-inflammatory cytokines like TNF-α, IL-1 and IL-6 to
create a ‘cytokine storm’ [109, 110]. These changes increase the expression of adhesion
molecules, costimulatory molecules, MHC antigens and chemokine gradients, which alert
the residual host and the infused donor immune cells [109]. The donor T cells infused
with the graft then interact with the primed APCs and the end result is activation,
proliferation, differentiation and migration of the alloreactive donor T cells. These
alloreactive donor T cells cause extensive damage to the GVHD target organs (skin, gut,
lung and liver) by cellular effectors like cytotoxic T lymphocytes (CTLs) and
inflammatory effectors like cytokines. It is believed that the onset and course of GVHD
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depend on the degree of major and minor MHC disparity as well as the T cell dose [16].
It was also reported that residual host APCs play an important role in the induction of
acute GVHD by CD8+ T cells in the minor MHC-mismatched model [111]. However,
Teshima et al found that the alloantigens located on the host epithelial tissues, which are
GVHD target tissues, are not required to trigger acute GVHD [112]. Tawara et al
investigated the role of APCs in the suppression of GVHD by donor Tregs and reported
that alloantigen expression by host APCs is necessary and sufficient for the induction of
GVHD protection by donor Tregs [52]. They also found that this requirement is
independent of their effect on the maintenance of Treg number and the production of IL10 or Indoleamine 2, 3-dioxygenase (IDO) by the host APCs [52].
Clinical GVHD can either be classified as acute or chronic [108]. Acute GVHD is
characterized by damage to the skin, liver and the gastrointestinal tract, while chronic
GVHD is characterized by more diverse manifestations which resemble autoimmune
syndromes with eosinophilic fasciitis, scleroderma-like skin disease and salivary and
lacrimal gland involvement [108]. For epidemiological studies, GVHD can be classified
as either acute or chronic based on the time at which it occurs after HCT [108, 113, 114].
With such classification, acute GVHD occurs within the first 100 days post
transplantation, while chronic GVHD occurs 100 days post transplantation [108].
However, many investigators prefer the pathological classification because the histology
associated with acute GVHD can still persists 100 days post transplantation, especially
when immunosuppressants are withdrawn from the patient [108]. Acute GVHD is
responsible for 15% to 40% of mortality and is the major cause of morbidity after
allogeneic HCT, while chronic GVHD occurs in up to 50% of patients who survive three
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months after HCT [84, 113]. The incidence of chronic GVHD can be as high as 70% in
human transplant recipients [108].
Apart from prophylaxis with immunosuppressive drugs, several strategies are
being investigated to reduce the risk of developing GVHD. Some of these strategies
include the selective depletion of alloreactive T cells in the donor graft, the use of
umbilical cord blood as the source of the donor graft and the use of monoclonal
antibodies and other novel drugs. Since GVHD is caused by the alloreactive T cells in the
donor graft reacting against the recipient tissues, eliminating the offending T cells before
graft infusion can effectively remove the risk of GVHD. However, patients who have had
T cell-depleted BMT are more likely to have tumor or malignancy relapse and are at an
increased risk for graft failure and infection. However, newer techniques to effectively
deplete the alloreactive donor T cells from the graft are being investigated. In one study,
CD62L(+) T cells (naïve and a subset of memory T cells) were selectively depleted and
the CD62L(-) T cells (a subset of memory T cells) failed to proliferate in response to
alloantigen and prevented the development of GVHD [115].
Bortezomib is a proteasome inhibitor that blocks the activation of nuclear factor
κB (NFκB) [116] and is FDA approved for the treatment of multiple myeloma [117,
118]. It was reported that bortezomib inhibits acute lethal GVHD in rodents after
allogeneic BMT with no observed adverse effects on myeloid recovery and donor
chimerism [119]. However, a later study by the same group reported that the time of
administration of bortezomib after BMT is critical for the effects of the drug on the
development of GVHD in mice. Early administration of bortezomib after BMT leads to
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effective prevention of GVHD, but a 5-day delay in administration of the drug could lead
to GVHD-related toxicity [120]. However, a subsequent clinical trial with bortezomib,
TAC, and MTX for GVHD prophylaxis after reduced-intensity conditioning allogeneic
stem cell transplantation (SCT) using human leukocyte antigen (HLA)-mismatched
unrelated donors show that Bortezomib is a promising novel immunomodulatory agent in
allogeneic transplantation [121].
Anti-CD3 mAbs have also been used in the treatment and prevention of GVHD.
Even though anti-CD3 mAb was effective when used to treat acute GVHD in a doseescalation trial, its use was associated with the risk of developing Epstein-Barr Virus
(EBV)-associated lymphoproliferative disorders [122]. Some murine anti-CD3 antibodies
can activate T cells in vivo and be counter-productive in the treatment of GVHD.
Therefore, the use of genetically engineered anti-CD3 mAb became a more valid option
to decrease side effects associated with murine anti-CD3 mAb. The nonmitogenic antiCD3 antibody, BC3 improved the clinical manifestations of GVHD in a phase I-II
clinical trial possibly by modulating T cell function [123]. Yu et al reported that nonFcR-binding anti-CD3 antibody induce apoptosis selectively in antigen-activated, cycling
T cells [124]. Later, the Anasetti group conducted a phase I clinical trial with visilizumab
(Nuvion) and reported that the humanized non-FcR-binding anti-CD3 mAb, which has
the ability to selectively induce apoptosis in activated T cells was effective in the
treatment of glucocorticoid-refractory acute GVHD [125]. Recent studies by Li et al
indicate that preconditioning with anti-CD3 monoclonal antibody before conditioning
with total body irradiation (TBI) prevents GVHD and retains the necessary GVL in a
HCT model of MHC-mismatched rodents [126]. Anti-CD3 mAb still represents a viable
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option for the prevention and treatment of GVHD. The level of disparity of MHC
between donor and recipient is an indicator of the risk of GVHD development. It is hoped
that with the advent of DNA-based tissue typing, increased accuracy and specificity of
HLA typing will lead to closer HLA matching between donor and recipient, hence a
reduction in GVHD [127].

Regulatory T cells: cellular therapeutic for GVHD.
Studies conducted with mixed lymphocyte reaction (MLR) experiments with both
mouse and human cells demonstrate the ability of regulatory T cells to suppress the
proliferative responses of alloreactive CD4+ T cells [128, 129]. It was reported that Tregs
are effective in suppressing autoimmune diseases [130] as well as solid organ
transplantation [131]. These findings lead researchers to investigate the role of Tregs in
GVHD. It was initially reported that depletion of CD4+CD25+ T cells from the donor
graft accelerated GVHD and increased lethality [132]. Additionally, Tregs have been
reported to be effective in preventing the development of GVHD across major and minor
MHC barriers in various HCT models [34, 37, 133, 134]. These studies demonstrate an
important role of Tregs in the development of GVHD. However, even though
physiological levels of endogenous CD4+CD25+ T cells may contribute to the
development and course of GVHD, their small number is likely insufficient to control the
overwhelming alloreactive T cell responses involved in major MHC-mismatched BMT
settings [16]. Furthermore, the use of Tregs in allogeneic HCT is very promising since it
was reported that the Tregs can suppress GVHD while preserving the GVL activity.
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However, three major issues still hinder the implementation of Tregs as immunotherapy
in the clinic. These include the low circulating numbers of Tregs in the peripheral blood,
the loss of suppressor activity following ex vivo expansion and the lack of Treg-specific
markers to purify ex vivo expanded Tregs [12]. However, the in vivo dynamics of Treg
trafficking and survival predict effective strategies to control GVHD after allogeneic
transplantation [135]. Despite these considerations, several clinical trials are ongoing that
adoptively transfer Tregs as immunotherapy to prevent the development of GVHD. One
group has transplanted freshly isolated donor Tregs while a second group has expanded
Tregs from cord blood with anti-CD3 and anti-CD28 coated microbeads and utilized
them in double umbilical cord blood transplantation [40, 41].

Antigen-specific regulatory T cells.
Tregs are effective in the prevention of GVHD and can spare GVL [35].
However, Tregs exert their suppression in vivo in a non-antigen-specific manner [49].
Since the use of HCT is primarily for the maintenance of graft-versus-tumor (GVT)
and/or GVL effect, non-antigen-specific suppression of Tregs included in the graft may
not be entirely beneficial to the recipient since susceptibility to infection presents itself
with the possibility of widespread suppression. The goal following HCT is for the
recipient to maintain an immune response against infections, while enabling specific
suppression of the deleterious GVHD-causing allo-reactive T cells. This may be achieved
by the generation and use of antigen-specific Tregs. Several groups have used
alloantigen-specific Tregs in the prevention of autoimmune diseases and have reported
19

their superiority to polyclonal Tregs. In experimental autoimmune encephalomyelitis
(EAE) mouse model for multiple sclerosis. Hori et al demonstrate that the effect of
myelin basic protein (MBP)-specific Treg cells was associated with specificity for MBP
[136]. A recent study also reported that TGFβ-induced myelin peptide-specific regulatory
T cells can mediate antigen-specific suppression in EAE [137]. Antigen-specific Tregs
was also used in the NOD mouse model for type 1 diabetes and Tregs which were
specific for a pancreatic autoantigen were more efficient at preventing diabetes than
polyclonal Treg cells [138, 139]. In a more recent study, Tonkin et al reported that Tregs
prevented diabetes in NOD mice only when their antigen was present in vivo in the
pancreas [140]. Additionally, autoimmune gastritis was also prevented by transfer of
stomach-specific Treg cells, but not with polyclonal Treg cells [141]. Our group had
generated antigen-specific iTregs by Foxp3 transduction and has shown that these cells
are more effective than polyclonal Tregs in preventing GVHD in a non-myeloblative
murine BMT model [142]. However, this study used the non-myeloblative BMT model
utilized gene transfection to generate the iTregs for the study. This is very difficult to
translate to the clinic, and therefore a study using a myeloblative BMT model would be
more representative of the human BMT. Also Foxp3 induction with the conversion of
peripheral CD4+CD25- naïve T cells to CD4+CD25+ regulatory T cells by TGFβ and IL-2
[55] provides a more translatable method for Treg generation.
The H-Y antigen has previously been implicated in GVHD involving male
recipients of female donors. miHAs have varied tissue distribution; some are restricted to
hematopoietic tissues [143-147], while others have ubiquitous tissue expression [98].
Pidala and Anasetti have proposed that the varied tissue distribution of miHA may be
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utilized for the production of antigen-specific iTregs in GVHD prevention [98]. The
antigen-specific Tregs with specificity for minor antigens that have broad tissue
distribution can be generated and these iTregs can selectively suppress donor alloreactive
T cells with specificity for the broad distribution minor antigens. This would selectively
abrogate the cells responsible for the development of aGVHD. However, these Tregs
would have no effect on the alloreactive T cells which have specificity for minor antigens
that are restricted to hematopoietic cells and thus preserve the GVL effect [98]. Specific
GVHD prevention with corresponding sparing of the GVL effect has great potential for
application to human transplantation.

CD28 costimulation and GVHD development.
Activation of naïve T cells by recipient alloantigen starts immediately after cell
transplantation and results in the development of severe acute GVHD. The CD28
costimulatory molecule plays an important role in the development of GVHD, contributes
to its pathogenesis and enhances its severity. Our group investigated the role of CD28 in
the development of GVHD by comparing the ability of wild-type (WT) and CD28
deficient T cells to initiate GVHD. We previously reported that CD28 signals contribute
to the pathogenesis of GVHD and enhance its severity [148]. CD28 costimulation is
important for cytokine production in the pathogenesis of GVHD [148]. In contrast, the
CTLA4-signal inhibits T cell response and reduces GVHD [149].
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Central Hypothesis
Our preliminary data suggests that strong CD28 costimulation has a suppressive
effect on the generation of iTregs in the periphery. We will therefore investigate which
CD28-mediated signal(s) are responsible for suppressing iTreg generation. The central
hypothesis is that strong CD28 costimulation has an important role in the suppression of
iTregs in the periphery. It is not known whether suppression of iTreg generation mediated
by CD28 costimulation contributes to development of GVHD. We will determine
whether suppression of iTreg generation mediated by CD28 costimulation has a role in
the T cell response in vivo. Further, based on the superiority of antigen-specific iTregs to
polyclonal Tregs in preventing autoimmune diseases, we also hypothesize that induced
Tregs with specificity for an antigen expressed on the recipient would be more effective
and specific than polyclonal nTregs in the prevention of GVHD. We will use the
following specific aims to test our hypotheses:

Specific Aims
1) Determine the effects of CD28 costimulation on iTreg generation in the periphery
2) Determine the role of Antigen-specific TGFβ-induced Tregs in the prevention of
GVHD after BMT.
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CHAPTER 2.
MATERIALS AND METHODS
Experimental Mice
C57BL/6 (B6) and BALB/c mice were purchased from the National Cancer
Institute (Bethesda, MD). Founders of CD28 WT and mutation Tg mice on B6
background, including CD28-WT, CD28-Lck, CD28-PI3K and CD28-Itk Tg strains,
were provided by Drs. X. Tai and A. Singer at the National Cancer Institute [23]. Each of
these 4 Tg strains was bred into CD28 knockout (KO) mice so that Tg CD28 molecules
were the only CD28 receptors expressed by the Tg T cells. We screened CD28 Tg mice
by FACS and selected the mice that expressed CD28 on CD4+ cells comparably among
different strains of mice. C57BL/6 (B6, H-2b), B6 that express congenic Ly5.1 or Thy1.1,
B6 bm12 and OT-II TCR transgenic (Tg) strains were purchased from the Jackson
Laboratory (Bar Harbor, ME). Foxp3gfp knock-in (KI) strain was obtained from
Rudensky’s laboratory at University of Washington (Seattle, WA) [19, 150]. OT-II
Foxp3gfp KI and (B6.OVA x bm12)F1 strains were produced by cross-breeding.
Luciferase-transgenic (Luc-Tg) strain on B6 background was kindly provided by Dr. R.
Negrin (Stanford University, CA) [151]. B6 OVA Tg under β-actin strain was kindly
provided by S. Schoenberger (La Jolla Institute for Allergy and Immunology, San Diego,
CA). These strains of mice were bred and all mice used in this study were housed in a
pathogen-free condition at H. Lee Moffitt Cancer Center & Research Institute (Tampa,
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FL). All experimental procedures were reviewed and approved by the Institutional
Animal Care and Use Committee.

Reagents and Antibodies
Recombinant mouse IL-2 and human TGFβ-1 were purchased from R&D systems
(Minneapolis, MN). Anti-mouse CD3 (clone 145.2C11) and CD28 (clone 37.51) mAbs
were produced and purified in our laboratory. Purified PE-conjugated anti-mouse/rat
Foxp3 (clone FJK-16s) was purchased from eBioscience (San Diego, CA). Other
fluorochrome-conjugated mAbs were purchased from eBioscience or Becton Dickinson
(San Jose CA).

T cell Purification
CD4+CD25- T cells were purified through negative selection using biotinylated
CD45R, CD11b, CD8a, TER, DX5 (eBioscience), CD25 and anti-biotin Micro Beads
(Miltenyi Biotec). The purity of CD4+CD25- cells ranged from 85 to 95%, but
CD4+CD25+ cells was always less than 1% among total CD4+ cells.

Induced Regulatory T cell Generation
With anti-CD3.
To generate polyclonal iTregs, CD4+CD25- T cells were seeded at 2.5 x 105/well
in 48-well plates and stimulated with 0.5-1.0 µg/ml soluble anti-CD3 mAb in the
presence of 1.25 x 106 irradiated syngeneic T-cell depleted (TCD) splenoctyes as APCs,
with and without TGF-β1 and IL-2 both at 2 ng/ml. Alternatively, CD4+CD25- T cells
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were stimulated by plate-bound anti-CD3 mAb at 5 or 10 ng/ml without or with platebound anti-CD28 mAb at various concentrations in the absence of APCs. In some cases,
additional pp1 was included in the culture at the concentrations indicated. After
stimulation for 4 days, cells were harvested for the measurement of Foxp3 expression, or
GFP expression if T cells from Foxp3gfp reporter mice were used.

Antigenic stimulation with OVA peptide.
To generate antigen-specific (OVA) iTregs, CD4+CD25- T cells from OT-II
Foxp3gfp KI mice were seeded at 2.5 x 105/well in 48-well plates and stimulated with 0.5
µg/ml OVA peptide in the presence of 1.25 x 106 irradiated syngeneic TCD-splenoctyes
as APCs, with 2 ng/ml TGF-β1 and IL-2 at 1 ng/ml. After incubation for 6 days, cells
were harvested and sorted for measuring CD4+CD25+GFP+ iTregs. Percentage of
CD4+CD25+GFP+ cells ranged from 20% to 60% among CD4+ cells. CD4+CD25+GFPcells were also sorted and used as controls.

Allogeneic stimulation.
To generate iTregs with allogeneic stimulation, B cells or bone marrow-derived
DCs (BM-DCs) from BALB/c mice were used to stimulate C57BL/6 CD4+CD25- T cells
with TGF-β and IL-2. CD4+CD25- T cells from the mutant strains were seeded at 200 x
103/well in 96-well plates and stimulated with 40 x 103/well LPS-activated B cells in the
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presence of TGFβ and IL-2. After stimulation for 6 days, cells were harvested for the
measurement of CD4, CD25 and Foxp3 expression by flow cytometry.

Flow Cytometry Analysis
Surface staining.
Two-, 3- , 4- or 5-color flow cytometry was performed to measure the expression
of surface molecules according to standard techniques. Analysis was performed using a
FACScan or FACS Calibur with CellQuest Pro version 5.2.2 (BD Biosciences) or the
LSR II with DIVA software.

Intracellular staining.
Multi-color flow cytometry was performed to measure intracellular Foxp3
expression according to the manufacturer’s instruction (eBiosciences, San Diego, CA).
Fluorescence conjugated-Abs were purchased from BD-Pharmingen (San Diego, CA) or
eBioscience (San Diego, CA). Analysis was performed by using a FACS Calibur or LSR
II instrument and CellQuest Pro version 5.2.1 (BD Biosciences) or FlowJo version 8.5.3
software (TreeStar, Ashland, OR). Other intracellular cytokines were measured after
stimulation with PMA and ionomycin in vitro for 4-5 hours with the addition of Golgi
Stop for the last 2 hours. The cells were then stained for surface expression of CD4,
Ly5.1 and Thy1.1, and for intracellular expression of IFN-γ, IL-17 and IL-10.
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CFSE labeling.
For measurement of proliferative response in vitro and in vivo, T cells were
labeled with CFSE (Molecular Probes). The CFSE dilution in T cells was analyzed by
flow cytometry. For measurement of proliferative response in vivo, the T cells were
labeled with CFSE and then adoptively transferred to mice via tail vein injections. After 3
days, the spleens were harvested and stained for surface expression of CD4.

Bone Marrow Transplantation
As recipients, BALB/c mice were exposed to 800 - 900 cGy of total body
irradiation (TBI), while (B6 x bm12)F1 were exposed to 1200 - 1300 cGy (2 doses of 600
- 650 cGy given 3 hours apart) of TBI. TCD-BM cells alone or in combination with
purified CD25- T cells from indicated donors were injected into recipients via tail vein
within 24 hours of irradiation. Recipient mice were monitored every other day for clinical
signs of GVHD, such as ruffled fur, hunched back, lethargy or diarrhea, and mortality.
Animals judged to be moribund were sacrificed and counted as GVHD lethality. In
separate experiments, cell expansion and iTreg generation of donor T cells were
measured in recipient spleen at indicated times after BMT. In some experiments, T cells
from Luc-Tg B6 donors were used as Teffs and transplanted into either BALB/c or (B6 x
bm12)F1 recipients. The recipient mice underwent bioluminescence imaging (BLI) to
tract the transplanted Teffs. Recipient mice were injected with luciferase substrate which
allowed serial imaging of the in vivo bioluminescent signal using an IVIS200 chargecoupled device imaging system (Xenogen).
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[3H] Thymidine Incorporation Assay
To access cell proliferative response, cultures were be pulsed with [3H] thymidine
(1 µCi) 8 hours before collection. The cells were harvested (Cell Harvester) and counted
in a liquid scintillation counter (Top Count, Perkin-Elmer) to measure proliferation.
Testing was done in triplicate.

Statistical Analysis
The log-rank test was used to detect statistical differences in recipient survival in
GVHD experiments. Student’s t test was used to compare percentages or numbers of
donor T cells.
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CHAPTER 3.
STRONG CD28 COSTIMULATION SUPPRESSES GENERATION OF
INDUCED TREGS THROUGH Lck SIGNALING
ABSTRACT
CD28 costimulation is required for the generation of naturally-derived regulatory
T cells (nTregs) in the thymus through lymphocyte-specific protein tyrosine kinase (Lck)
signaling. However, it is not clear how CD28 costimulation regulates the generation of
induced Tregs (iTregs) from naïve CD4 T-cell precursors in the periphery. To address
this question, we induced iTregs (CD25+Foxp3+) from naïve CD4 T cells (CD25-Foxp3-)
by T-cell receptor stimulation with additional transforming growth factor β (TGFβ) in
vitro, and found that the generation of iTregs was inversely related to the level of CD28
costimulation independently of interleukin-2 (IL-2). By using a series of transgenic mice
on CD28-deficient background that bears WT CD28 or mutated CD28 in its cytosolic tail
incapable of binding to Lck, phosphoinositide 3-kinase (PI3K) or IL-2–inducible T-cell
kinase (Itk), we found that CD28-mediated Lck-signaling plays an essential role in the
suppression of i iTreg generation under strong CD28 costimulation. Furthermore, we
demonstrate that T cells with the CD28 receptor incapable of activating Lck were prone
to iTreg induction in vivo, which contributed to their reduced ability to cause graftversus-host disease. These findings reveal a novel mechanistic insight into how CD28
costimulation negatively regulates the generation of iTregs, and provide a rationale for
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promoting T-cell immunity or tolerance by regulating Tregs through targeting CD28signaling.

Background and Rationale
Regulatory T cells (Tregs) play an essential role in the maintenance of
immunological tolerance to prevent autoimmune disease. The development of Tregs in
the thymus requires Foxp3, a member of transcription factors characterized by their
winged helix-forkhead DNA-binding domain [152]. Although it is widely accepted that
natural Tregs develop in the thymus (also termed nTregs), compelling evidence indicates
that Tregs with an identical phenotype can be induced in the periphery from CD4+ nonTreg precursors under certain conditions. For example, all CD4+ cells from RAG-/- TCR
transgenic (Tg) mice are CD25-, but a small proportion of these cells convert to a CD25+
Treg phenotype after adoptive transfer into antigen-bearing mice or mice that have been
administered a tolerizing dose of peptide antigen [153, 154]. Furthermore, De novo
generation of CD4+CD25+ Tregs from CD4+CD25- cells can also occur in thymectomized
mice [155]. Such Tregs that are induced in the periphery are also termed induced Tregs
(iTregs). Although our understanding of the microenvironment for iTreg development in
vivo is still limited, it is clear that TCR stimulation, TGFβ and IL-2 are required for their
development [55, 60, 156, 157].
A crucial regulator of Tregs is the CD28 receptor, a dominant costimulatory
molecule for T cell activation. The first clue to the critical role of the CD28 family in
nTreg function was the observation that prevention of CD28 ligation with CTLA4-Ig
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exacerbated autoimmune disease in NOD mice [74]. Mice deficient for CD28 or its
ligands (B7, CD80 and CD86) have substantially reduced number of nTregs [23, 74]. As
a consequence, NOD mice lacking CD28 develop more rapid and severe autoimmune
diabetes compared to wild-type (WT) mice. Recent studies indicate that CD28 is essential
for nTreg development in the thymus and for nTreg survival and homeostasis in the
periphery [23, 158]. Thus, while these mice are lacking potent costimulation (CD28) for
T effector cells (Teffs), they are also lacking nTregs, the most effective mediators of selftolerance, yielding a balanced deficit that results in the preservation of antigen-mediated
activation [75].
A potential role of CD28 in the generation of iTreg has not been rigorously
investigated. Conversion of conventional CD4+CD25- T cells into Tregs occurs in
thymectomized mice and requires B7 costimulation [155]. Furthermore, CD28
costimulation is required for the generation of iTregs from naïve CD4+CD25- T cells
through production of IL-2 [77]. However, there is also scattered evidence suggesting
that high levels of CD28 costimulation reduce Foxp3 expression and limit iTreg
generation through undefined mechanism(s) [13, 159]. In this study, we clearly
demonstrate that the high levels of CD28 costimulation suppress generation of iTregs
from naïve CD4 T cells while promoting expansion of Teffs. By using a series of Tg
mice on CD28-deficient background that bears either WT CD28 or mutated CD28 in its
cytosolic tail that is incapable of binding to Lck, PI3K or Itk, we found that strong CD28
costimulation suppresses iTreg induction through Lck-signaling but independent of IL-2
production.

31

CD28 Costimulation through Soluble anti-CD28 mAb
CD28 is required for the full development of nTregs in the thymus and for
homeostasis of nTregs in the periphery. Besides developing in the thymus, Tregs can also
be generated or differentiated from naïve CD4 T cells in the periphery, and these Tregs
are termed iTregs. How CD28 costimulation modulates the generation of iTregs is
unclear. We investigated the effect of CD28 costimulation on iTreg generated from naïve
CD4+CD25-Foxp3- cells in vitro during TCR-stimulation in the presence of TGFβ.
CD4+CD25-GFP cells were purified from Foxp3gfp reporter mice and were stimulated
with soluble anti-CD3 mAb plus various concentrations of agonistic anti-CD28 mAb.
After culturing for 4 days, iTregs (CD4+GFP+) were generated in the presence of TGFβ
(Fig. 1A). Anti-CD28 mAb inhibited iTreg generation in a dose dependent manner, in
percentage (Fig. 1B) as well as in absolute cell number (Fig. 1C). In contrast, anti-CD28
stimulation increased the numbers of Teffs (CD4+GFP-) (Fig. 1C) and IL-2 production
(Fig. 1D) in a dose-dependent manner, which is consistent with the established concept
that agonistic anti-CD28 mAb provides T-cell costimulation.
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Figure 1. Soluble anti-CD28 mAb reduces iTreg generation in vitro. CD4+GFP- cells
were purified by FACS sorting from Foxp3gfp reporter mice and stimulated with anti-CD3
mAb plus irradiated TCD splenocytes as APCs in the absence or presence of TGFβ.
Soluble anti-CD28 mAb was added at different concentrations into the culture. Four days
after stimulation, cultured cells were harvested and measured for CD4, GFP and
intracellular Foxp3 expression. A. The data show the percentage of GFP+ (upper panel)
or Foxp3+ (lower panel) cells on gated CD4+ cells. B. The data are presented as the mean
of percentage of Teffs (GFP-) and Tregs (GFP+) cells in total CD4+ cells in triplicate
wells. C. The data are presented as the mean ± 1 SD of absolute numbers of Teffs
(CD4+GFP-) and Tregs (CD4+GFP+) cells in triplicate wells. D. In separate experiments,
cultured cells were harvested and measured for CD4 and GFP expression whereas culture
supernatant was measured for IL-2 production. The data show the percentage of GFP+ on
gated CD4+ cells (left Y-axis), and IL-2 production (right Y-axis). The data are presented
as the mean ± 1 SD in triplicate wells, and represent 1 of 3 replicate experiments.
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CD28 Costimulation through Plate-bound anti-CD28 mAb
Because T cells receive other co-stimulatory signals provided by APCs in the
culture, it is possible that signals other than CD28 were also required for the inhibition
of iTreg generation. To address this possibility, purified CD4+CD25- T cells were
stimulated with cross-linking anti-CD3/anti-CD28 plus TGFβ in the absence of APCs
(Fig. 2A). Under this culture condition, we also observed that anti-CD28 inhibited iTreg
generation in a dose-dependent manner and increased expansion of Teffs (Fig. 2C),
indicating that other signals from APCs may not have a significant effect in this
phenomenon. Because CD28 costimulation promotes IL-2 production, it is possible that
strong CD28 costimulation may suppress iTreg generation through high levels of IL-2.
However, when a high concentration of exogenous IL-2 at 2 ng/ml was added to the
culture, it did not suppress iTreg generation and did not affect the suppression of iTreg
generation by strong CD28 costimulation (Fig. 2). We therefore conclude that strong
CD28 costimulation suppresses the generation of iTregs independently of IL-2
production. However, since there was a difference both in percentage and absolute
number of the Tregs generated without and with IL-2 in the presence of low but not high
levels of anti-CD28 (Fig. 2), it is possible that IL-2 can circumvent inhibition mediated
by lower levels of CD28 costimulation.
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Figure 2. Plate-bound anti-CD28 mAb reduces iTreg generation in vitro.
CD4+CD25- cells were purified from spleen and lymph node cells from normal B6 mice
and stimulated with plate-bound anti-CD3 mAb plus anti-CD28 mAb in the absence of
APCs. Exogenous TGFβ was also included in the culture with or without additional IL-2.
Four days after stimulation, cultured cells were harvested and measured for CD4, CD25
and intracellular Foxp3. A. The expression of CD25 and Foxp3 is shown on gated CD4+
cells. B. The data are presented as the mean of percentage of Teffs (CD25+Foxp3-) and
Tregs (CD25+Foxp3+) cells in total CD4+ cells in triplicate wells. C. The data are
presented as the mean ± 1 SD of absolute numbers of Teffs (CD4+CD25+Foxp3-) and
Tregs (CD4+CD25+Foxp3+) cells in triplicate wells. The data represent one of 4 replicate
experiments.
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Lck-signal is Critical for CD28-mediated Suppression of iTreg Generation
Through its cytoplasmic motifs, CD28 can recruit and activate several kinases
including Lck, PI3K and Itk [82]. To explore the question of which CD28-mediated
signal(s) are responsible for suppressing iTreg generation, we utilized a set of CD28 Tg
mice that express CD28 receptors with different mutations in the CD28 cytosolic tail:
CD28 with an unmutated cytosolic tail (hereafter CD28-WT); CD28 with mutations in
P187A and P190A that abrogates Lck binding (CD28-Lck); CD28 with a mutation in
Y170F that abrogates PI3K binding (CD28-PI3K); and CD28 with mutations in P175A
and P178A that abrogates Itk binding (CD28-Itk) (Fig. 3). To identify the CD28 kinaseactivating domains (cytoplasmic motifs) required for suppressing iTreg generation,
purified CD4+CD25- T cells from CD28-WT, CD28-Lck, CD28-PI3K or CD28-Itk Tg
mice were stimulated with cross-linking anti-CD3/anti-CD28 plus TGFβ without APCs.
In the absence of exogenous IL-2, additional anti-CD28 inhibited iTreg generation from
CD28-WT naïve CD4 T cells in a dose-dependent manner (Fig. 4A). iTreg generation
from CD28-Itk cells was also inhibited by anti-CD28. These data showed that strong
CD28 costimulation suppressed iTreg generation, and Itk activation mediated by CD28
did not play a significant role in this process. In contrast to CD28-WT or CD28-Itk cells,
anti-CD28 did not inhibit iTreg generation from CD28-PI3K cells and even increased
iTreg generation from CD28-Lck cells (Fig. 4A), indicating that CD28-mediated PI3K
and Lck signals are required for the suppression of iTreg generation.
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Figure 3. CD28 transgenic mice. All the CD28 transgenes were bred into CD28-/- mice
to eliminate the endogenous CD28 expression. These CD28 transgenes were introduced
in a human CD2-based transgenic vector, which drives expression in immature
thymocytes and mature T cells. The point mutations (bold and underlined) in the
cytosolic tails were generated by changing Y (tyrosine) to F (phenylalanine) and P
(proline) to A (alanine).
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Because CD28-mediated Lck activation is critical for IL-2 production [23, 160,
161] and CD28-mediated PI3K activation also contributes to IL-2 production, [162-164]
it was possible that IL-2 produced by CD28-WT or CD28 Itk T cells stimulated by high
concentrations of anti-CD28 was responsible for the suppression of iTreg generation,
whereas CD28-PI3K or CD28 Lck T cells were unable to produce high levels of IL-2. In
the presence of exogenous IL-2, anti-CD28 suppressed iTreg generation similarly from
CD28-WT or CD28-Itk T cells in a dose-dependent manner, but suppression was less on
CD28-PI3K T cells and was minimal on CD28-Lck T cells (Fig. 4B). These results
demonstrate that strong CD28 costimulation suppresses the generation of iTregs through
Lck- and PI3K-signaling independently of IL-2 production. Because CD28-mediated
Lck-signaling plays the most important role in this process, we focused on the Lckpathway for further studies.
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Figure 4. CD28-mediated Lck and PI3K signals contribute to the suppression of
iTreg generation. CD4+CD25- cells were purified from a series of Tg mice on CD28deficient background that bear WT-CD28 or unmutated CD28 in its cytosolic tail
incapable of binding to Lck (CD28-Lck), PI3K (CD28-PI3K) or Itk (CD28-Itk). Purified
CD4+CD25- cells were then stimulated with plate-bound anti-CD3 and indicated
concentrations of anti-CD28 in the presence of TGFβ. The culture was without (A) or
with additional IL-2 (B). Four days after stimulation, cultured cells were harvested and
measured for expression of surface CD4, CD25 and intercellular Foxp3, and
CD4+CD25+Foxp3+ cells were considered as iTregs. The data show percent relevance of
iTreg generation with anti-CD28 to that without anti-CD28. The numbers were presented
as the mean ± 1 SD of percent relevance as pooled data from triplicate experiments.

39

CD28- and TCR-mediated Lck Signaling Contribute to iTreg Generation
Differently
Because Lck activation can be induced by TCR- or CD28-engagement among
others, we investigated the contribution of CD28- and TCR-mediated signaling in the
generation of iTregs. This was addressed by using Src-specific inhibitor (pp1) in cultures
of CD28-WT or CD28-Lck T cells stimulated by anti-TCR with or without anti-CD28
mAb in the absence of APCs. Lck signaling comes from the TCR in CD28-Lck T cells,
whereas Lck signaling comes from both CD28 and TCR in CD28-WT T cells. In the
absence of anti-CD28, pp1 reduced the generation of iTregs from CD28-WT or CD28Lck T cells to a similar extent (Fig. 5A), indicating that TCR-mediated Lck signaling
promotes the generation of iTregs in the absence of CD28 costimulation. On the other
hand, in the presence of anti-CD28, pp1 restored the generation of iTregs from CD28WT cells thereby neutralizing the anti-CD28 suppressive effect, whereas the inhibitor had
no effect on the generation of iTregs with CD28-Lck cells (Fig. 5B). It is of interest that
pp1 diminished iTreg generation from CD28-Lck T cells in the absence (Fig. 5B) but not
in the presence of anti-CD28 mAb (Fig. 5B). The reason is not clear, but other signals
(i.e. PI3K) derived from CD28 ligation through anti-CD28 might overcome the inhibition
through Lck blockade as data in figure 4 suggest.
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Figure 5. Lck-activation through TCR and CD28 regulates iTreg generation.
CD4+CD25- cells isolated from CD28-WT and CD28-Lck Tg mice were stimulated with
plate-bound anti-CD3 in the presence of TGFβ, IL-2 and indicated concentrations of pp1.
Cells were also stimulated without (A) or with (B) 40 µg/ml plate-bound anti-CD28
mAb. Four days after stimulation, cultured cells were harvested and measured for
expression of surface CD4, CD25 and intracellular Foxp3. The data show mean ± 1 SD
of percent Tregs (CD25+Foxp3+ among gated CD4+ cells) in triplicate wells, and the data
represent one of 3 replicate experiments.
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Effect of Inhibition of Lck Signaling on T-cell Division
Inhibition of Lck signaling might affect T-cell division and therefore interfere
with iTreg generation. To address this issue, we labeled T cells with CFSE and tested
how pp1 affected TCR-driven cell division. Under the culture condition with exogenous
IL-2, we did not observe a significant effect on T-cell division with pp1 at the
concentrations tested (Fig. 6). These data indicate that CD28-mediated Lck signaling
primarily contributes to the suppression of iTreg generation, in which TCR-mediated
Lck signaling played a very little role.
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Figure 6. Lck activation regulates T-cell division and iTreg generation in vitro.
CFSE labeled CD4+CD25- T cells from CD28-WT mice were stimulated with platebound anti-CD3 mAb in the presence of TGFβ, IL-2 and indicated concentrations of pp1.
Cells were also stimulated without (upper panel) or with (lower panel) plate-bound antiCD28 mAb. Four days after stimulation, cultured cells were harvested and measured for
CD4 and Foxp3 expression and CFSE profile. The data show Foxp3 expression and
CFSE profile on gated CD4+ cells, and represent 1 of 2 replicate experiments.
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Strong CD28-signal Derived from B7 Suppresses iTreg Generation
As strong CD28 costimulation with an agonistic anti-CD28 mAb could
suppress iTreg generation, we further investigated whether strong CD28 costimulation
elicited by its natural ligands B7 (CD80 and CD86) would also suppress the generation
of iTregs in vitro. CD4+CD25- T cells were purified from Foxp3gfp reporter mice and
stimulated with naïve or LPS-activated allogeneic B cells from BALB/c mice. As
expected, LPS activated B cells expressed much higher levels of CD86 than naïve B
cells (Fig. 7A). Under the culture condition with TGFβ and IL-2, ~70% of iTregs
(GFP+CD25+) were generated from naïve CD4 T cells stimulated by allogeneic naïve B
cells, but a much lower percentage of iTregs was generated when stimulated with
allogeneic, LPS-activated B cells (Fig. 7B). Moreover, the addition of CTLA4-Ig to
block B7:CD28 interactions increased iTreg generation in a dose-dependent manner
(Fig. 7C). These results confirm that CD28-costimulation elicited by high expression of
B7 on activated B cells was responsible for the suppression of iTreg generation in vitro.
We asked further questions whether iTregs induced after stimulation with B cells were
suppressive and whether their activities were different when generated with resting
versus activated B cells. To this end, polyclonal nTregs and iTregs generated with
allogeneic B cells were isolated by FACS sorting and used as Tregs to suppress the
allogeneic response of naïve B6 T cells to BALB/c APCs. As expected, nTregs
suppressed alloresponse in high ratios of Treg:Teff up to 1:16. The iTregs generated
with allogeneic B cells suppressed alloresponse even in low ratios up to 1:64 regardless
of resting or activated B cells (Fig. 7D), confirming the function and specificity of
iTregs generated in vitro.
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In separate experiments, we further tested whether iTreg generation would be
reduced through high levels of CD28 costimulation in vivo. To do so, we used adoptive
cell transfer model that was established previously in our laboratory [77]. Purified
CD4+CD25- T cells from Ly5.1+ B6 Foxp3gfp reporter mice were transferred into
sublethally irradiated syngeneic WT B6 or B7.1/7.2 double deficient recipients. The
percentage of iTregs generated in WT recipients was significantly higher than in B7deficient recipients (p < 0.001), confirming our previous observation that CD28-signal at
base levels is required for optimal generation of iTregs in vivo. Under this situation,
iTreg generation was significantly reduced with LPS stimulation in WT but not B7deficient recipients (Fig. 7E). These results suggest that inflammation caused by LPS
limited iTreg generation from naive CD4 T cells in vivo, and B7/CD28 interaction was
largely attributed to reduced iTreg generation. These data extended our in vitro
observations that LPS-stimulation increased B7 expression by B cells (Fig. 7 B and C)
or dendritic cells (Fig. 8), and those activated APCs induced iTreg generation at much
lower levels compared with non-activated APCs. Taken together, we concluded that
strong CD28 costimulation signals derived from the B7:CD28 ligation suppress iTreg
generation both in vitro and in vivo.
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Figure 7. Strong CD28-signal derived from B7 suppresses iTreg generation. A.
CD86 expression is shown on resting and LPS-activated B cells (B220+). B. CD4+CD25cells isolated from Foxp3gfp reporter mice on B6 background were stimulated with
resting or activated allogeneic B cells from BALB/c mice in the presence of TGFβ and
IL-2. Six days after stimulation, cultured cells were harvested and measured for
expression of CD4, CD25 and GFP. The data show mean ± 1 SD of percent Tregs (%
CD25+GFP+ on gated CD4+ cells) in triplicate wells. C. The culture condition was the
same as (B), except that LPS-activated B cells were used and CTLA4-Ig at various
concentrations was added into the culture. The data present fold of increase in the
generation of iTregs (CD25+GFP+) cells among gated CD4+ cells) in the culture with
CTLA4-Ig relevant to that without CTLA4-Ig. The numbers were presented as the mean
± 1 SD of fold increase in triplicate wells. The data presented in each panel were
reproduced in at least 3 replicate experiments.
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Figure 8. Effect of CD28-mediated signaling on Treg generation. Naïve CD4+CD25T cells from CD28-WT and CD28-Lck mice were stimulated with BMDC in the presence
of TGFβ and IL-2. CD4 and Foxp3 expression were measured 6 days after stimulation.
Percentage of Foxp3 cells were shown on gated CD4 cells.
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Suppression of iTreg Generation Through CD28-mediated Lck-Signal Contributes
to T-cell Pathogenicity In Vivo
Lastly, we addressed whether suppression of iTreg generation mediated by CD28costimulation would be relevant to T-cell responses in vivo. To this end, we compared
the ability of CD4 and CD8 T cells isolated from CD28-WT and CD28-Lck mice in the
induction of acute graft-versus-host disease (GVHD). Because development of nTregs is
severely impaired in CD28-Lck mice, nTregs (CD4+CD25+) were removed from donor
T-cell graft for a fair comparison. We observed that all the recipients of CD28-WT T
cells died within 5 weeks after BMT, but the recipients of CD28-Lck T cells died
significantly later and 40% survived long-term (p = 0.005) (Fig. 9 A and B). We
hypothesized that increased iTreg generation from CD28-Lck CD4 T cells might be
accounted for by the reduced GVHD mediated by CD28-Lck T cells. To test this
hypothesis, we tested the ability of CD28-WT or CD28-Lck CD4 T cells in the
induction of GVHD in the combination of WT CD8 T cells, where the only difference
was CD4 cells. Under this situation, CD28-WT but not CD28-Lck CD4 T cells were
capable of causing severe GVHD (Fig. 9C and D). To directly test the role of CD28mediated Lck-signal in iTreg generation in vivo, purified CD4+CD25- T cells from
CD28-WT and CD28-Lck mice were transferred to irradiated BALB/c mice. After 2
weeks, significantly higher percentages of iTregs were generated from CD28-Lck T
cells than CD28-WT T cells in vivo (Fig. 9E). The absolute number of iTregs generated
from CD28-Lck T cells was also substantially higher than that from CD28 WT T cells
(2.5 ± 0.1 x 105 vs. 0.6 ± 0.5 x 105 per spleen). Thus, elevated iTreg generation was
associated with diminished GVHD development. Additional or alternative mechanism
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which CD28-Lck T cells induced significantly less GVHD could be resulted from
impaired activation and expansion of Teffs without CD28-mediated Lck signaling.
Using CFSE-labeling, we observed that both CD28-WT and CD28-Lck T cells divided
rapidly in irradiated allogeneic BALB/c recipients (Fig. 9G). As expected, a subset of
donor T cells produced IFNγ in the allogeneic recipients, but CD28-WT T cells had
slightly higher percentage of IFNγ-producing cells than CD28-Lck T cells on CD4+ but
not CD8+ cells (Fig. 9H). Taken together, these data support the hypothesis that
enhanced iTreg generation with CD28-Lck T cells contributes to the decreased ability of
these T cells to induce acute GVHD.
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Figure 9. CD28-mediated Lck signaling regulates GVHD development and iTreg
generation in vivo. BALB/c mice were lethally irradiated (800 cGy) and transplanted
with 5 x 106 TCD-BM cells alone or plus 1 x 106 T cells (CD4+ or CD8+ CD25-) from
CD28-WT or CD28-Lck mice. Recipient mice were monitored throughout experimental
period for survival (A) and weight change (B). Using the same BMT setting as A and B,
0.5 x 106 CD8+ cells from normal B6 donors alone or plus 0.5 x 106 CD4+ cells from
CD28-WT or CD28-Lck mice were transplanted. Data show recipient survival (C) and
weight changes (D) days after BMT. E. BALB/c mice were lethally irradiated (800 cGy)
and transplanted with 5 x 106 TCD-BM cells alone or plus 1 x 106 T cells (CD4+CD25-)
from CD28-WT and CD28-Lck mice. Two weeks after transplantation, recipient spleens
were harvested and measured for expression of surface CD4, CD25 and intercellular
Foxp3. Percentage of Tregs (CD25+Foxp3+) on gated donor T cells (H2Kb+CD4+) is
shown in each mouse of total 3 mice per group, and the data represent 1 of 3 replicate
experiments. In separate experiments, CFSE-labeled T cells (CD4+ or CD8+ CD25-)
isolated from CD28-WT and CD28-Lck mice were transplanted into lethally irradiated
(800 cGy) BALB/c mice at 2 x 106 per mouse. Four days after transplantation, recipient
spleens were harvested and measured for CFSE profile, expression of surface CD4 and
H2Kb, and intracellular IFNγ. Expression of CD4 and H2Kb was shown on live spleen
cells (F). CFSE profile (G) and intracellular IFNγ expression (H) were shown on gated
donor CD4 (H2Kb+CD4+) or CD8 (H2Kb+CD4-) T cells. The data represent 1 of 2
replicate experiments.
50

Discussion and Conclusion
The data presented in this report indicate that strong CD28 costimulation
suppresses the generation of iTregs from naïve CD4 T cells, primarily through Lcksignaling. It is well established that CD28 costimulation positively regulates T-cell
response by promoting IL-2 production, cell cycle entrance, activation and survival of T
cells [82, 165]. On the other hand, CD28 costimulation plays a critical role in
development of nTregs in thymus and in maintenance of nTregs in the periphery, by
which CD28 contributes to maintaining self-tolerance [166]. In addition, our previous
work indicates that low or base level of CD28 costimulation is required for iTreg
generation through IL-2 production primarily mediated by CD28-mediated Lck [77]. The
current finding adds a new facet to the regulatory function of CD28 costimulation, which
at high levels can promote T-cell response by shutting down iTreg generation from naïve
CD4 T cells. This new concept fits well with the overall mission of T-cell responses.
Under acute infection, high levels of CD28 costimulation not only promote activation and
expansion of effector T cells, but also suppress generation of iTregs that permits effective
immune responses against infectious agents. In contrast, under quiescent situations or in
cancer, low levels of CD28 costimulation not only limit activation and expansion of
effector T cells, but also promote homeostasis of nTregs and generation of iTregs
permitting immune tolerance to self or tumor antigens.
Efficient development of nTregs in the thymus relies on CD28 costimulation
through its cytosolic Lck-binding motif and c-Rel leading to activation of NF-κB [78-81].
Although the same motif is required with CD28 costimulation for IL-2 production,
CD28-mediated nTreg development is independent of IL-2 production [23]. Ironically,
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our current work demonstrates that the same Lck-binding motif is again required for the
suppression of iTreg generation mediated by strong CD28-costimulation independently
of IL-2 production. Thus, the same CD28-mediated Lck-signal exclusively of IL-2
production is responsible for efficient development of nTregs in the thymus, but also for
the control of iTreg generation in the periphery. Taken together, we propose that, through
Lck- and Rel-dependent signaling pathway, CD28 costimulation at base level is required
for nTreg development in the thymus and iTreg generation under quiescent situation,
whereas CD28 costimulation at high levels limits iTreg generation during active immune
responses. How the CD28-mediated Lck-signal regulates these two distinct processes is
currently unclear, although apparently T cells are in different stages (immature vs.
mature) and CD28-costimulation is at different levels (base vs. elevated).
Interestingly, although TCR-ligation also activates Lck, the TCR-mediated Lcksignal promoted rather than suppressed the generation of iTregs (Fig. 5). Under the
culture condition specified in this report, high levels of TCR-stimulation (i.e. high
concentrations of anti-CD3 mAb) without CD28-costimulation were not suppressive to
iTreg generation (data not shown). The different outcomes may have resulted from the
distinguished patterns of Lck activation mediated by TCR and CD28, respectively. Upon
TCR engagement, Lck is recruited and remains only transiently in the immunologic
synapse. Subsequently, Lck's SH3 domain interacts with C-terminal proline motif of
CD28, which disrupts formation of potentially inhibitory intramolecular Lck interactions
between the Lck SH3 domain and its kinase domain that interfere with Lck activity [167].
In this way, CD28 costimulation greatly increases both the intensity and duration of Lck
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activity at the immunological synapse of TCR-engaged T cells, which may be critically
important for suppressing the generation of iTregs.
A recent study by Gottschalk et al elegantly demonstrate that TCR ligand density
and potency determine induction of iTregs in the periphery, and conclude that a low
density of a strong TCR agonist is optimal to induce a persistent generation of iTregs in
vivo [168]. Their study was focused on T cell responses under non-inflammatory
condition, where CD28 costimulation was at low or base level. Because CD28
costimulation reduces the extent of TCR ligation required for effective T-cell responses
likely by lowering the threshold of TCR signal transduction for T-cell activation and
promoting the formation of an immunological synapse [169, 170]. CD28 regulates iTreg
induction could be through modifying TCR signaling. However, we propose that the
combined signals through TCR and CD28 determine the proper levels of iTreg induction
and Teff generation from naïve CD4 T cells.
Using a GVHD model, we showed that CD28-Lck donor T cells caused
significantly less GVHD than WT donor T cells (Fig. 7A and 7B). Furthermore, in
combination with WT CD8 T cells, WT CD4 T cells induced severe GVHD whereas
CD28-Lck CD4 T cells failed to do so (Fig. 7C and 7D). Because significantly higher
rate of iTregs were generated from CD28-Lck than WT CD4 T cells (Fig. 7E), we
conclude that enhanced generation of iTregs contributed to decreased GVHD induced by
CD28-Lck donor T cells although lower effector function might still be a part of the
mechanism. Our data differ from the observation that CD28 costimulation was
paradoxically inhibitory in MHC class II-mismatched murine cardiac graft rejection and
in the development of autoimmune diabetes in NOD mice [74, 171]. The outcomes in
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these 2 studies reflect the important role of CD28 costimulation at base levels in the
generation and maintenance of Tregs under non-inflammation situation. In contrast,
inflammation is created under myeloablative allogeneic BMT, in which CD28
costimulation presumably at high levels would in turn limit the generation of iTregs and
facilitate GVHD development.
In summary, in understanding how CD28 costimulation promotes productive Tcell response, our study reveals a novel mechanism that CD28 costimulation promotes
immunity by suppressing the generation of iTregs in the periphery. CD28 costimulation
executes this negative regulation on iTregs through its Lck-binding motif independently
of IL-2 production. Given CD28 provides a predominant costimulation and Tregs is one
of the most critical regulatory components in many if not all aspects of immunology, the
current finding may provide the rationale for promoting T-cell immunity or tolerance by
regulating iTreg induction through targeting CD28-signaling in many immunologic
responses under autoimmunity, transplantation and cancer development.
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CHAPTER 4.
EFFICIENT AND SELECTIVE PREVENTION OF GRAFT–VERSUS-HOST
DISEASE BY ANTIGEN-SPECIFIC INDUCED TREGS VIA LINKED
SUPPRESSION
Abstract
Naturally occurring regulatory T cells (nTregs) suppress the development of
GVHD and may spare graft-versus-leukemia (GVL) effect [35]. Because nTreg is a rare
population in a healthy individual, the limited source and the non-selective suppression
are major hurdles towards the application of nTregs in the control of clinical GVHD after
allogeneic HCT. An alternative approach is to generate induced Tregs (iTregs) from
naïve CD4 precursors, but the effectiveness of iTregs in the control of GVHD is highly
controversial and requires further investigation. The other critical but unsolved issue on
Treg therapy is how to achieve antigen (Ag)-specific tolerance that distinguishes GVHD
and GVL effect. To address the important issues on the effectiveness of iTregs and Agspecificity of Tregs, we generated Ag-specific iTregs and tested their potential in the
prevention of GVHD in pre-clinical BMT model. CD4+CD25+Foxp3+ iTregs generated
from OT-II TCR transgenic T cells specific for OVA target Ag efficiently prevented
GVHD induced by polyclonal T effector cells (Teffs) only in the allogeneic recipients
that express OVA protein but not in OVA- recipients. The efficacy of these Ag-specific
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iTregs was significantly higher than polyclonal iTregs. As controls, OT-II CD4+Foxp3cells had no effect on GVHD development in OVA- recipients and exacerbated GVHD in
OVA+ recipients when transplanted together with polyclonal Teffs. Because the iTregs
recognize OVA whereas Teffs recognize alloAg bm12, our data reveal for the first time
that Tregs prevent GVHD through a linked suppression. Mechanistically, OT-II iTregs
expanded extensively, and significantly suppressed expansion and infiltration of Teffs in
OVA+ but not in OVA- recipients. These results demonstrate that Ag-specific iTregs can
prevent GVHD efficiently and selectively, providing a proof of principle that Ag-specific
iTregs may represent a promising cell therapy for their specificity and higher efficacy in
allogeneic HCT.

Background and Rationale
Allogeneic BMT or HCT offers great promise for the treatment of a variety of
diseases including cancer, autoimmunity, aplastic anemia, and other hematopoietic
diseases. However, GVHD remains the major complication following this therapeutic
procedure because it leads to high morbidity and mortality in patients [84, 108]. Despite
the magnitude of this complication and the extensive efforts to overcome this problem, no
clinical strategy has been established to efficiently prevent GVHD without producing a
broad immune suppression. Recent evidence indicates that the use of Tregs
(CD4+Foxp3+) is one of the promising approaches to control GVHD in numerous mouse
models [34-39] in addition to early clinical trials [40, 41] .
Although it is widely accepted that natural CD4+Foxp3+ Tregs are developed in
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the thymus (termed nTregs), accumulating evidence suggests that T cells with regulatory
function may also arise in the periphery under certain conditions and are termed induced
Tregs (iTregs). The full extent of differences and similarities between iTregs and nTregs
has not yet been defined [172]. Due to the infrequency of nTregs in the peripheral blood
and the difficulty in isolating sufficient nTregs with adequate purity, much attention has
been placed on the use of in vitro-expanded nTregs with emphasis on retaining their
regulatory capabilities. Other studies have focused on iTregs generated from naive
CD4+CD25- cells to obtain a regulatory cell population to suppress immune responses in
vitro and in vivo. However, the use of iTregs as an immunotherapy is still controversial
concerning their stability in Foxp3 expression [142, 173-176].
Because Tregs need to be activated by their specific antigen (Ag) to exert their
suppressive function, it is understood that polyclonal populations of Tregs will only have
limited efficacy on a per cell basis to regulate allogeneic responses due to the low
frequency of alloantigen-reactive Tregs within the whole population. Although large
numbers of polyclonal Tregs are capable of preventing GVHD in rodents, broad
polyclonal suppression is expected. Therefore, Ag specificity of Tregs is critical to
selective suppression mediated by these cells. In experimental autoimmune disease
models, Ag-specific Tregs are highly effective in controlling autoimmune diabetes,
gastritis and encephalomyelitis [137, 138, 177]. However, the advantage of using Agspecific Tregs in the prevention of GVHD has not yet been investigated.
We previously generated Ag-specific iTregs by foxp3 transduction and
demonstrated that they persist long-term in vivo and suppress GVHD in a non57

myeloablative BMT model when activated by the cognate Ag; either constitutively
expressed or introduced via immunization [142]. In our previous study, however, a nonmyeloablative BMT model was used that is not representative of clinical HCT, and
iTregs were generated through gene transfection. In the current study, we addressed these
two important issues and demonstrate that TGFβ-induced, Ag-specific iTregs efficiently
and selectively prevent GVHD in a murine model of myeloablative BMT.

TGFβ-induced, Ag-specific iTregs Prevent GVHD in an Ag-dependent Manner
Recent progress made by many groups including ours indicates that iTregs can be
generated from naïve CD4 T cells upon TCR stimulation in the presence of TGFβ [55,
77, 157]. iTregs are effective in suppressing autoimmune diseases, but their effect in
controlling GVHD is controversial and remains to be further investigated. For this reason,
we generated OT-II TCR Tg and foxp3/gfp KI mice by cross-breeding. OVA-specific
iTregs were then generated from OT-II Tg and foxp3/gfp KI CD4+CD25- T cells by
stimulating them with OVA peptide in the presence of TGFβ (Fig. 10).
We then tested whether OVA-specific iTregs (CD4+CD25+GFP+) were able to
prevent GVHD induced by polyclonal T cells in a B6 → (B6 x bm12)F1 BMT model, in
which donor CD4+ T cells (Teffs) recognize mismatched recipient MHC II alloAg
(H2bm12). To specifically activate iTregs, (B6.OVA x bm12)F1 mice were used as
recipients that ubiquitously express OVA. The bm12 mutation can present OVA peptide,
but OT-II T cells cannot recognize this MHC/peptide complex. In this setting, Teffs at
indicated dose induced 50% GVHD lethality. Similar numbers of OVA+ and OVA58

recipients were used for the Teff alone group, but the same results was observed in
survival or weight loss regardless of OVA expression (data not shown). Additional iTregs
completely prevented GVHD lethality in OVA+ (p = 0.01) but not in OVA- recipients (p
= 0.8) (Fig. 11), indicating that activation of iTregs was required for their suppressive
function. CD4+GFP- control cells had no effect on GVHD in OVA- recipients, or even
accelerated GVHD in OVA+ recipients as Teffs (Fig. 11). These results demonstrate that
Ag-specific iTregs are potent in suppressing GVHD in an activation-dependent manner.
Because the iTregs recognize OVA whereas Teffs recognize alloAg bm12, these data
reveal that Tregs prevent GVHD through a linked suppression.
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Figure 10. Isolation of iTregs and nTregs. A, generation and purification of iTregs.
CD4+CD25- cells were purified from spleen and lymph node of OT-II TCR Tg and
foxp3/gfp KI mice. These purified T cells were stimulated with OVA peptide at 0.5 µM in
the presence of irradiated TCD-splenocytes. TGFβ was added in the culture at 2 ng/ml for
Treg generation. Four to six days after culture, cells were harvested and stained for CD4,
CD25 and GFP expression. The phenotype of cultured cells is shown on gated live cells
(2 left panels). CD4+ CD25+GFP+ and CD25+GFP- cells were separated by FACS sorting
(2 right panels). B, purification of nTregs. CD4+ cells were isolated through negative
selection from spleen and lymph node of B6 foxp3/gfp KI mice. These CD4+ enriched
cells were stained for CD4 and CD25 expression. The phenotype of these cells is shown
on gated live cells (2 left panels). CD4+ CD25+GFP+ and CD25-GFP- cells were separated
by FACS sorting (2 right panels).
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Figure 11. The effect of TGFβ-induced Tregs in GVHD. OVA+ or OVA- (B6 x
bm12)F1 mice were lethally irradiated and transferred with 5 x 106 TCD-BM alone or
plus 1 x 106 CD4+ T cells (Teffs) from B6 donors. OVA-specific iTregs
(CD4+CD25+GFP+) were generated and purified by FACS sorting as shown in figure 1.
OVA-specific iTregs or controls at 0.5 x 106/mouse each were added into donor graft.
Recipient survival (A) and body weight changes (B) are shown. Ten recipients were
included in each group except that 5 mice were used in GFP+ or GFP- cells to OVAgroups. The data are pooled from 2 replicate experiments using a similar setting.
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TGFβ-induced, Ag-specific iTregs are Significantly More Effective in the Prevention
of GVHD then Polyclonal iTregs
To further evaluate the potency of OVA-specific iTregs in the prevention of
GVHD, these iTregs were used at 1:4 or 1:8 ratio of Treg: Teff. We found that GVHD
lethality was completely prevented at either cell dose (Fig. 12 A and B). To compare the
potency of Ag-specific versus non Ag-specific iTregs, polyclonal iTregs were generated
from CD4+CD25- cells of B6 foxp3/gfp KI mice by stimulating with anti-CD3 mAb in the
presence of TGFβ as shown in our previous work [77]. In contrast to Ag-specific iTregs,
the polyclonal iTregs had a partial effect only at 1:2 ratio of Treg:Teff in suppressing
GVHD (Fig. 12C and D). These data indicate that Ag-specific iTregs are ~ 8-fold more
effective than polyclonal iTregs in GVHD prevention.
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Figure 12. The potency of Ag-specific and polyclonal iTregs in suppressing GVHD.
A and B, OVA+ (B6 x bm12)F1 mice were lethally irradiated and transferred with TCDBM alone or plus 1.6 x 106 CD4+CD25- T cells (Teffs alone) from B6 donors. OVAspecific iTregs (CD4+CD25+GFP+) were generated from OT-II T cells and were added at
0.2 or 0.4 x 106 each into donor graft. C and D, OVA- (B6 x bm12)F1 mice were lethally
irradiated and transferred with TCD-BM alone or plus 1 x 106 CD4+CD25- T cells (Teffs
alone) from B6 donors. Polyclonal iTregs (CD4+CD25+GFP+) generated from WT B6 T
cells with anti-CD3 stimulation plus TGFβ were added at 0.25 or 0.5 x 106 each into
donor graft. Recipient survival (A and C) and body weight changes (B and D) are shown.
Five or six recipients were included in each group for both experiments.
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Ag-specific iTregs Suppress the Expansion, Activation and Infiltration of Teffs In
Vivo
We next assessed the suppressive effects of Ag-specific iTregs on Teffs in vivo.
Taking advantage of Luc-Tg mice, the expansion and infiltration of Luc-Tg Teffs can be
measured in vivo over time using BLI assay. Because low dose of Teffs (5 x 105/mouse)
was transferred into B6 mice (black) that are less sensitive for signal detection, no
significant BLI signal was detected on day 7. The BLI detected on day 17 and 28
demonstrate that additional OT-II iTregs significantly reduced Teff expansion in OVAexpressing recipients (Fig. 13A and B). The distribution of the BLI signal suggests that
the Teffs infiltrated more broadly to liver and gut without iTregs whereas Teffs were
more constrained in spleen with iTregs (Fig. 13A).
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Figure 13. The effect of Ag-specific iTregs on expansion and infiltration of Teffs.
Lethally irradiated OVA+ (B6 x bm12)F1 mice were transplanted with B6 TCD-BM plus
0.5 x 106/mouse Teffs (CD4+CD25-) isolated from Luc-Tg mice on B6 background. One
group of recipients was also transferred with additional 0.25 x 106/mouse OT-II iTregs
(CD4+CD25+GFP+). Donor Teffs were monitored in recipient mice 17 and 28 days after
BMT. A, animals were imaged from the ventral position for quantification of donor T
cells. B, the average of relative signal intensity of 4 mice per group, and the data
represent one of 2 replicate experiments.
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To further evaluate the effect of iTregs on expansion and activation of Teffs, we
transferred Teffs isolated from B6 Ly5.1+ mice and iTregs generated from Thy1.1+ OT-II
CD4 precursor (1:2 ratio of Treg: Teff) along with TCD-BM isolated from normal B6
donors into OVA+ or OVA- (B6 x bm12)F1 recipients. Seven days after BMT, we
measured Teffs (CD4+Ly5.1+) in recipient spleen and liver (Fig. 14A and D). There was
an average of 1.9 ± 0.4 x106/mouse Teffs in the spleen of the recipients transferred with
Teffs alone, 0.9 ± 0.1 x106 in the OVA+ recipients transferred with Teffs plus iTregs, and
1.8 ± 0.8 x106 in the OVA- recipients transferred with Teffs plus iTregs, respectively
(Fig. 14B). The data indicate that iTregs significantly reduced Teff expansion in the
OVA+ (p = 0.005) but not the OVA- recipients (p = 0.8). In the liver, the number of Teffs
was also significantly lower in the OVA+ recipients transferred with Teffs plus iTregs
than those with Teffs alone (Fig. 14E, p = 0.004), suggesting that iTregs reduced Teff
expansion and/or infiltration in recipient liver, a major GVHD target organ. Because
peripheral lymphoid organs are important for T cell activation, we examined the
migration of iTregs to recipient lymph nodes and spleen relevant to antigen stimulation in
vivo. In a separate experiment, we observed that the percentages of iTregs among CD4+ T
cells were 36.3 ± 5.3% vs. 17.1 ± 3.1% in lymph nodes and spleen of OVA+ recipients,
respectively (n = 4, p = 0.0007). However, the percentages of iTregs among CD4+ T cells
were less than 1% in lymph nodes and spleen of OVA- recipients (n = 4, p = 0.08). These
results suggest that Tregs preferentially reside in lymph nodes upon antigen stimulation.
To evaluate the activation of Teffs, we measured intracellular expression of IFNγ
and IL-17, and calculated the numbers of IFNγ- and IL-17-producing Teffs in the
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recipient spleen. The number of IFNγ-producing Teffs in the OVA+ recipients transferred
with Teffs plus iTregs was significantly lower than that in the recipients of Teffs alone (p
= 0.005), whereas there was no difference between the recipients with Teffs alone and
those OVA- recipients with Teffs plus iTregs (p = 0.9) (Fig. 14C). There were very few
Teffs that produced IL-17 (< 2%) and no significant difference among those groups (data
not shown). These results indicate that iTregs also reduced Teff activation when iTregs
were activated by specific Ags.
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Figure 14. Effects of Ag-specific iTregs on expansion and activation of Teffs. Teffs
cells (CD4+CD25-) were isolated from WT Ly5.1+ donors and transferred at 1 x
106/mouse together with TCD-BM into lethally irradiated OVA- or OVA+ (B6 x bm12)F1
mice. The other 2 groups were transferred with OT-II Thy1.1+ iTregs at 0.5 x 106/mouse
into OVA- or OVA+ (B6 x bm12)F1 recipients. Seven days after BMT, recipient spleen
(A-C) and liver (D and E) were harvested for measuring expansion and activation of
donor Teffs. A, top panels show percentages of CD4+ cells in live cells, and bottom
panels show expression of Ly5.1 (Teffs’ maker) and Thy1.1 (iTregs’ marker) on gated
CD4+ live cells in recipient spleen. B, absolute numbers of Teffs (CD4+Ly5.1+) are
shown in average ± 1 SD. C, spleen cells were also measured for intracellular expression
of IFNγ, and absolute numbers of IFNγ+ Teffs (CD4+Ly5.1+) are shown in average ± 1
SD. D, top panels show percentages of CD4+ cells in live cells, and bottom panels show
expression of Ly5.1 (Teffs’ marker) and Thy1.1 (iTregs’ marker) on gated CD4+ live
cells in recipient liver. E, absolute numbers of Teffs (CD4+Ly5.1+) in the liver are shown
in average ± 1 SD. Each group includes 3 or 4 mice, and the data represent 1 of 3
replicate experiments.
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After Adoptive Transfer In Vivo, iTregs Expanded to Higher Numbers While
nTregs had More Stable Expression of Foxp3
We assessed the expansion and stability of iTregs in vivo. In experiments with the
same setting as in figure 14, OT-II iTregs (CD4+Thy1.1+) expanded extensively in OVA+
but not OVA- recipients (Fig. 15A and B, p < 0.001). To further compare the expanding
potential between iTregs and nTregs, we isolated polyclonal nTregs (CD4+CD25+GFP+)
from naïve B6 foxp3/gfp KI mice (Ly5.2+) as standard controls (Fig. 9B). The expansion
levels for OT-II iTregs in OVA+ recipients were significantly higher than that of nTregs
(Fig. 15A and B, p = 0.001), indicating that Treg expansion depended on Ag-stimulation
in vivo.
Recent publications suggest that iTregs are less stable than nTregs in maintaining
Foxp3 expression. To address this concern, we gated on CD4+Thy1.1+ Tregs and
analyzed their Foxp3/GFP expression. Because Tregs were highly purified through FACS
sorting for GFP expression (Fig. 9A), the percentage of GFP- cells in gated CD4+Thy1.1+
cells would reflect the loss of Foxp3 expression. Polyclonal nTregs (CD4+CD25+GFP+)
from naïve B6 foxp3/gfp KI mice were also used as standard controls. Under
myeloablative allogeneic BMT, average of 43.6 ± 5.4% nTregs kept their GFP expression
7 days after cell transfer, whereas 29.4 ± 2.8% and 24.8 ± 2.8% iTregs kept their GFP in
OVA+ and OVA- recipients, respectively (Fig. 15D and E). Foxp3 expression was less
stable in iTregs than nTregs (p = 0.003), whereas the stability of iTregs was similar in the
recipients regardless of OVA expression (Fig. 15D and E). To measure activation of
Tregs, intracellular IFNγ and IL-10 were measured. We found that 7 days after BMT
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there was an average of 20.0 ± 3.4% and 4.1 ± 0.5% IFNγ+ cells among Ag-specific
iTregs and polyclonal nTregs, respectively. Furthermore, the number of IFNγ+ Agspecific iTregs was significantly more in the OVA+ than OVA-recipients and
significantly more than that of nTregs in recipient spleen (Fig. 15C, p < 0.001). In
conclusion, Treg expansion depended on Ag-stimulation and iTregs were activated and
expanded more extensively than nTregs, but iTregs were less stable than nTregs in Foxp3
expression upon Ag-stimulation under myeloablative allogeneic BMT.
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Figure 15. Expansion and stability of Tregs in the recipients after allogeneic BMT.
Experimental setting is the same as described in figure 5. One additional group of
recipients was transferred with 0.5 x 106/mouse nTregs isolated from naïve B6 foxp3/gfp
KI mice (Ly5.2+Ly5.1-). A, percentages of Thy1.1+Ly5.1- (iTregs) or Ly5.2+Ly5.1- cells
(nTregs) on gated CD4+ live cells in recipient spleen. B, absolute numbers of iTregs or
nTregs are shown. C, absolute numbers of IFNγ+ iTregs or nTregs are presented per
spleen. D, GFP expression on gated iTregs or nTregs in recipient spleen. E, percentages
of GFP+ cells among gated iTregs or nTregs are shown in average ± 1 SD. Each group
includes 3 or 4 mice, and the data represent 1 of 3 replicate experiments.
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Discussion and Conclusion
Besides regulating autoimmunity, CD4+CD25+ Tregs also control allogeneic
responses. Therefore, research on understanding and applying Tregs in the setting of
HCT has been an active field in recent years . Due to low frequency of nTregs, current
approaches in attempt to apply Tregs in clinical HCT are focused on adoptive transfer of
polyclonal, ex vivo expanded, nTregs into transplant recipients before or after stem cell
transplantation. Isolating and expanding polyclonal nTregs is feasible [178, 179];
however, questions remain about their efficacy and the consequences of broad immune
suppression in vivo. E.g. these polyclonal nTregs may have a low potency in controlling
GVHD and produce non-selective immune suppression without discriminating for GVH
and GVL reactions.
The current study is aimed at increasing the potency and selectivity of Treg
therapy. By using TGFβ-induced Ag-specific iTregs, we showed that Ag-specific iTregs
were highly effective in preventing GVHD in a clinically relevant murine model of
allogeneic BMT in an Ag-dependent manner (Fig. 11). The current study substantially
extended the previous work by us and others showing that in vitro generated iTregs were
effective in suppressing allogeneic responses in bone marrow or solid organ
transplantation [142, 173-175]. However, our result is in contrast to a recent report by
Konencke et al. that TGFβ-induced polyclonal iTregs were not effective in preventing
GVHD presumably due to the instability of Foxp3 expression [176]. We interpret that the
differences in the protocol of generating iTregs, the specificity of iTregs and GVHD
model may contribute to the distinct outcome in these two studies. Higher levels in
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expression of Ag-specific iTregs were likely resulted from higher levels of Ag-driven
proliferation and less dependent on Ag and cytokine signals in recipients of pre-activated
and dividing iTregs versus resting nTregs.
A potential concern is that iTregs may not have stable Foxp3 expression due to
their status of epigenetic modification and lose their suppressive activity in vivo [180]. In
fact, some studies have showed that in vitro generated iTregs were less suppressive than
nTregs [181, 182]. However, there is also substantial evidence in the literature supporting
that iTregs were as or more effective than nTregs in suppressing immune responses in
vivo [55, 66, 137, 177, 183-186]. To address this concern on iTreg stability, we directly
compared Foxp3 stability of iTregs and nTregs and observed that iTregs were less stable
than nTregs in Foxp3 expression under allogeneic BMT (Fig. 6D and E). However,
iTregs underwent substantially higher levels of Ag-driven expansion than nTregs (Fig.
15B), which may compensate for their inferior stability relative to that of nTregs.
Remarkably, we showed that Ag-specific iTregs were able to prevent GVHD in 100%
recipients at 1:8 ratio of Tregs to Teffs (Fig. 11A). In contrast, using the same murine
BMT model where BM plus CD4+ T cells were transplanted into lethally irradiated bm12
recipients, Taylor et al. indicated that in vitro activated and expanded, polyclonal
CD62Lhigh nTregs could prevent GVHD in nearly 100% at 3:1 ratio of Tregs to Teffs
[38]. Taken together, these data indicate that Ag-specific iTregs can be ~24-fold more
effective than the most potent polyclonal nTregs tested so far. Considering the frequency
of alloreactive T cells, we observed that significantly more Ag-specific iTregs produced
IFNγ after activation by cognate Ag than polyclonal nTregs after activation by
alloantigens (20% vs. 4%), confirming that Ag-specific iTregs were more activated than
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polyclonal nTregs. Because IFNγ production by Tregs is critical for their suppressive
function in vivo [187], high level of IFNγ production by Ag-specific iTregs also
correlated with their superior suppressive activity to polyclonal nTregs.
A fundamental issue regarding Treg-mediated suppression not yet being
addressed is whether Tregs execute their regulatory function through Ag-specific, Aglinked or bystander suppression in vivo. The current study made it clear that iTregs must
be activated by their cognate Ag in vivo in order for them to exert their suppressive
function and to control GVHD (Fig. 11 and 12). Because iTregs recognize nominal Ag
(OVA) whereas Teffs recognize allo-Ags (bm12), the results indicate that iTregs do not
have to recognize the same Ag as Teffs for Tregs to suppress the responses elicited by the
Teffs in vivo and strongly support the notion that linked suppression is operational under
allogeneic BMT settings. Our data are consistent with the results reported by Tang et al.
that monoclonal Tregs (BDC2.5 TCR Tg) specific for an islet Ag are highly effective in
controlling experimental diabetes induced by polyclonal diabetogenic Teffs [138]. These
studies indicate that Treg-mediated immunosuppression does not have to be exclusively
Ag-specific, which seems contradictory with the results observed by Joffre et al [96] or
those by Zhang et al [137]. Using BM rejection model, Joffre et al. showed that Tregs
specific for donor alloAgs selectively prevent rejection of donor BM but not third-party
BM, both of which were transplanted into the same recipient [96], suggesting that Tregmediated suppression is Ag-specific. Likewise, using an EAE model, Zhang et al. showed
that myelin proteolipid protein (PLP)139-151-specific iTregs were effective at suppressing
EAE induced by the cognate (PLP)139-151 peptide, but not by (PLP)178-191 peptide or even
a mixture of the 2 peptides [137]. It is not clear why Tregs mediated suppression with
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exquisite Ag-specificity in some studies but not the others. What is clear is that Tregs can
induce Ag-specific or Ag-linked suppression but not bystander suppression in vivo. No
bystander suppression in vivo is also evident in which the generation of donor-reactive
iTregs prevents graft rejection without compromising immunity to a viral pathogen [188].
Isolating and expanding polyclonal nTregs has been shown to be feasible [178,
179]; however, questions remain about their efficacy and Ag specificity in vivo. E.g.
although they can be expanded multi-fold in vitro, generating the absolute number of
Tregs needed to treat a patient successfully may still be a challenge [189]. We want to
emphasize that, unlike polyclonal alloreactive Tregs expanded with allogeneic APCs in
vitro [133, 190, 191] or induced in vivo [12, 192, 193], the Ag-specific Tregs investigated
in the current study are monoclonal and each of them specifically recognizes the cognate
Ag, which likely contributes to the high efficacy of these cells in suppressing GVHD. In
this proof-of-concept study the iTregs are monoclonal and uniformly recognize the
cognized antigen with high affinity, thus caution should be noted from a translational
perspective, as the results could be different with a population of polyclonal antigenspecific iTregs. Our current effort focuses on evaluating the effects of polyclonal iTregs
specific for MHC or miHA antigens for better translational potential. The current study
also provides evidence that iTregs prevent GVHD through linked suppression in an Agactivation dependent manner, which likely has a broad impact in understanding how
Tregs execute their suppressive function under biological or pathological situations. In
clinical application, this finding indicates that iTregs specific for a miHA restricted on
parenchymal tissues can distinguish GVHD versus GVL. Although creating Ag-specific
Tregs is facilitated by the use of TCR Tg cells in mice, this approach will be more
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challenging in humans. However, the approach can be applied in the clinic to treat
hematological tumors by generating and using iTregs specific for restricted miHAs on
GVHD target tissues, because human T cells can be primed by miHAs in vitro. In
conclusion, this study provides a proof of principle that Ag-specific iTregs may represent
a promising Treg therapy for their specificity and higher efficacy in allogeneic HCT.
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CHAPTER 5:
CONCLUDING REMARKS
CD28 costimulation through Lck signaling is required for nTreg generation in the
thymus [23] and for iTreg generation in the periphery [77]. In the current study we found
that strong CD28 costimulation suppresses the generation of iTregs from naïve precursors
through Lck signaling. The Lck signaling pathway is present both in TCR signaling and
in CD28 costimulation. We have shown that CD28-mediated Lck signaling is required
for the suppression of iTreg generation in the periphery, while the TCR-mediated Lck
signaling is primarily associated with iTreg generation (Fig. 5). We have also shown that
Teffs from mice with abrogated CD28-mediated Lck signaling induce less GVHD than
mice with intact CD28-mediated Lck signaling, which indicates an important role of
CD28-mediated Lck signaling in GVHD induction. Recipient mice that received Teffs
from CD28-Lck mice exhibited increased iTreg generation compared with Teffs from
CD28-WT mice (Fig. 9), which indicate that diminished GVHD development is
associated with elevated iTreg generation. These findings have implications for therapy
since the Lck signaling can be targeted to regulate immunity or tolerance. Drugs targeting
kinases for the treatment of inflammation and autoimmune disorders have become a
focus for some pharmaceutical and biotech companies [194]. It was reported that
inhibition of Lck with small molecules has significant potential for therapeutic
immunosuppression [195]. Several studies have been done using small molecule Lck
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inhibitors. One such study used AA-770041, a novel and selective small molecule
inhibitor of Lck which prevents heart allograft rejection across major histocompatibility
barriers for at least 60 days [196]. Dasatinib is an oral small molecule inhibitor of Abl
and Src family tyrosine kinases (SFK), including p56Lck (Lck) and was recently approved
for the treatment of adults with chronic myeloid leukemia (CML) and resistance or
intolerance to prior therapy, including imatinib [197-199]. It was demonstrated that
Dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine
production, and in vivo T cell responses. However, in this study, the signal transduction
and proliferative responses via IL-2 remained essentially intact, suggesting that Dasatinib
displays specificity for TCR signaling [200]. The Lck signaling pathway plays an
important role in CD28 co-stimulation as well as in TCR signaling. The Lck kinase
activity is critical for TCR-mediated signaling, leading to normal T-cell development and
activation [201]. Inhibition of Lck is expected not only to suppress activation of Teffs,
but also to increase the generation of iTregs. Thus, given the potent ability and specificity
of Dasatinib to inhibit Lck activity, the effect of Dasatinib in the development of GVHD
should be investigated.
Our data indicates that CD28-mediated PI3K signaling may play a role in the
suppression of iTreg generation in the periphery (Fig.4). The PI3K-regulated pathway is
one of the major signaling pathways and is activated by TCR, IL-2R, and CD28
stimulation, leading to T-cell activation, proliferation, and cell survival [83]. Akt, a
serine-threonine kinase, is a key downstream effector of the PI3K pathway which in
response to PI3K activation, phosphorylates and regulates the activity of various targets
including kinases, transcription factors and other regulatory molecules. Akt functions as a
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key regulator of various critical cell functions including glucose metabolism, cell
proliferation and survival. Therefore, the role of PI3K in iTreg suppression should be
investigated.
The application of alloantigen-specific iTregs for the prevention of GVHD
following allogeneic HCT seems very promising. Our results show a proof-of-principle
that Tregs that are specific for peptides in the recipient can efficiently protect against
polyclonal Teffs. The focus must now be on generating Tregs with specificity for miHA
present on the epithelial tissues of recipients and testing their effects in similar
transplantation models. The goal is to generate Tregs that are specific for ubiquitous
alloantigens present on epithelial tissues but will spare hematopoietic antigens. This
system can be easily translated to the clinic and holds promise to prevent GVHD and
spare the GVL effect. The challenge will be to identify miHA that are present on
epithelial tissues but absent on hematopoietic tissues.
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